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TRANSGENIC MOUSE MODELS OF HUMAN LUNG DISEASES 
by S. Damak 
Transgenic mice can provide useful probes into complex biological systems. We have 
produced transgenic mice expressing human neutrophil elastase (HNE) in their lungs in 
order to better understand the elastase-antielastase theory and produce an animal model 
for emphysema, as well as mice expressing the human Krev-l in order to test its activity in 
vivo. 
Disruption of the protease anti-protease balance in the lung is believed to playa key role in the 
aetiology of emphysema. In an attempt to produce an animal model for emphysema, we have 
generated transgenic mice by microinjection of HNE genomic DNA under the control of the 
rabbit uteroglobin (UO) promoter. Eight independent transgenic lines were generated. 
Analysis of total RNA by Northern hybridisation showed strong expression of HNE mRNA 
in transgenic lung of 6 out of 8 lines, and weak expression in a seventh line. 
Immunohistochemistry using specific anti-HNE antibodies indicated the presence of HNE 
protein in the bronchial epithelium. The protein was detected immunologically in 
bronchoalveolar lavages, indicating that HNE protein was secreted. On Western blotting of 
lavage fluid, a biotinylated anti-HNE antibody detected two bands of approximately 30,000 
and 80,000 Mr corresponding to free and complexed HNE, respectively. No HNE activity 
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was detected in the bronchoalveolar lavages of transgenic mice. Examination of mouse lung 
sections occasionally revealed mild signs of emphysema but there was no difference in 
incidence of emphysema between transgenic and wild-type groups. 
Mice of -the NJ strain are useful models of lung cancer because they develop tumours 
spontaneously or after treatment with ethyl carbamate. These tumours are thought to arise 
either from the Clara cells (papillary tumours) or from the alveolar type 2 cells (alveolar 
tumours), and, like many human lung adenocarcinomas, involve K-ras activation. 
Transformation with K-ras can be reversed by co-expression of the Krev-l gene in tissue 
culture. To test the tumour suppressor activity of Krev-l in vivo we have produced 
transgenic NJ mice expressing Krev-l in their lungs under the control of the rabbit 
uteroglobin promoter. Sixty-six mice (35 transgenic and 31 non-transgenic) from 3 lines 
were given ethyl carbamate and the numbers of lung tumours were compared between 
transgenic and non-transgenic animals. The mean number of ethyl carbamate-induced 
lung tumours was 21.7 ± 1.3 (s.d.) in transgenic mice and 26.9 ± 1.6 in non-transgenic 
littermates (p<O.Ol). These data demonstrate the activity of Krev-l in vivo. In a second 
experiment, 8 mice (3 transgenic and 5 non-transgenic) were given ethyl carbamate and 
the resulting tumours were dissected and examined microscopically. The numbers of 
alveolar tumours were 4.7 per transgenic mouse and 3.8 per non-transgenic mouse, 
whereas the numbers of papillary tumours were 5.3 per transgenic mouse and 6.8 per non-
transgenic mouse. As UG-driven trans genes are expressed in Clara cells, this reduction in 
the percentage of papillary tumours in transgenic mice is consistent with the Clara cell 
origin of at least some of the papillary tumours. 
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During the course of this work, a plasmid with a protruding G at each end that can be used 
as a positive control for end-filling prior to blunt-end ligation was developed. 
We also developed a simple method for efficient blunt-end ligation. We have shown that 
construction of recombinant plasmids can be done efficiently if ligation is first carried out 
at high DNA concentration, to favour intermolecular events, then the DNA is diluted to 
low concentration to favour intramolecular events. Using this method, the number of 
recombinant plasmids obtained was about 10 times higher than in the control ligation with 
the generally recommended DNA concentration. 
Keywords: 
Transgenic mice, tumour suppressor, emphysema, Krev-l, neutrophil elastase, lung, 
cancer, recombinant DNA, blunt-end ligation, animal model, uteroglobin, All 
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General introduction 
The ability to manipulate the mammalian genome in vivo has resulted in significant 
progress in many areas of biology. Since the pioneer work of Wagner and co-workers in 
the early eighties (Wagner et al 1981), the production of transgenic mice by pronuclear 
microinjection of one cell-embryos has become a powerful molecular biology tool that has 
been widely used to probe complex biological systems and to make animal models for 
human diseases. 
An example of a complex biological process is carcinogenesis. The events that induce the 
multistep progression from a normal cell phenotype to a fully cancerous state can be 
simplistically divided into activation of growth-promoting genes (oncogenes) and 
inactivation of growth-suppressor genes (tumour suppressor genes). In reality, the 
process is much more complex and involves the immune system, which tolerates the 
cancerous cells even though in many cases they express non-self antigens, programmed 
cell death (apoptosis), and cell to cell communication. Transgenic mice offer a very 
powetful tool to study genes involved in carcinogenesis in vivo, where all the parameters 
involved in carcinogenesis are present, as opposed to tissue culture where many important 
factors (for example the immune system) are not taken into consideration. 
Another area where transgenic mice are particularly useful is the production of well 
charactelised animal models of human diseases. These animals are invaluable tools for a 
better understanding of the disease and for testing therapeutic drugs. Often, when there is 
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no spontaneous genetic animal model for a paIticular disease, transgenic animals 
constitute the only source of experimental material. 
Our previous work and expelience with the rabbit uteroglobin promoter, which directs the 
expression of heterologous genes to the lungs of transgenic mice, was the origin of our 
interest in lung diseases. Here, we investigate the use of transgenic mice as models of 
human lung disease. Part of this work involved expressing the human neutrophil elastase 
gene in the lungs of transgenic mice in order to produce an animal model for emphysema. 
Another part consisted of testing the activity of the putative tumour suppressor gene Krev-
1 in vivo by expressing it in the lungs of NJ mice, a strain susceptible to spontaneous and 
carcinogen-induced lung cancer. 
Producing and studying transgenic mice involves the construction of sometimes complex 
recombinant DNA molecules, some of which involve many cloning steps where blunt-end 
ligation of DNA fragments is unavoidable. In the course of our work with transgenic 
mice, we have developed an efficient method for blunt-end ligation and constructed a 
plasmid useful as a positive control of end-filling plior to blunt-end ligation. 
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1.1 Transgenic mice 
Chapter 1 
Review of the literature. 
The ability to introduce foreign or modified genes into the genome of mice provides a 
valuable tool for the dissection of complex biological processes and for the production of 
animal models of human diseases. The introduction of cloned DNA into the genome of 
mice through microinjection of fertilised eggs was achieved for the first time in 1980 
(Gordon et al 1980). The first genes to be injected were the herpes simplex thymidine 
kinase gene, and rabbit and human ~-globin genes (Gordon et al 1980, Brinster et al 1981, 
Wagner et al1981a and 1981b). These achievements attracted the attention of the world 
when it became obvious that the integrated trans gene was transmitted to the following 
generations, was expressed in the correct tissue at the proper time of development and was 
affecting the phenotype of mice. Transgenic mice harbouring the human growth factor 
under the control of a mouse metallothionein promoter that showed a dramatic growth 
were the most publicised example of what could be achieved through trans genesis 
(Palmiter et al 1982). Since then the technique has been applied to several genes and hali 
been used to probe complex biological systems. Several excellent reviews are available in 
the literature (Gordon and Ruddle 1985, Levine and Tilghman 1986, Palmiter and Brinster 
1986). 
The method used by Gordon and colleagues to produce the first transgenic mouse is 
essentially the same nowadays. To make transgenic mice, young immature femate mice 
are superovulated and the fertilised eggs collected by flushing the oviducts. The one-cell 
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zygotes are- then examined under a microscope usingintelference contrast which allows 
visualisation of the pronuclei and microinjected with the DNA using micromanipulators. 
Eggs that survive the microinjection are implanted in a pseudopregnant female and allowed 
to develop to term. After delivery, transgenic mice are identified by Southern blot 
analysis of DNA extracted frem a tail biopsy at-weaning. 
Several attempts have been made to simplify this technique, but despite some successes, 
none of the new methods has had any widespread use. The most publicised attempt was 
by Lavitrano et al (1989) who reported that integration, transmission and expression of 
transgenes can be very simply achieved by soaking sperm in DNA then using the sperm for 
in vitro fertilisation of mouse eggs. The publication ofthe article was followed by a race 
by several laboratories involved in transgenesis to replicate the work of Lavitrano et al. 
After several attempts, it was evident that the results were not reproducible. Of over 1300 
mice produced by several leading laboratories using this procedure, none was found to 
have integrated the foreign DNA (Brinster etal 1989). An attempt to replicate the 
experiment ina different laboratory using reagents provided by Lavitrano did not result in 
the birth of any transgenics (Brinster et al1989) and it is currently generally accepted that 
spelm-mediated transgenesis is not as easy as described. 
Transgenesis via infection of mouse embryos by recombinant viruses engineered to carry 
exogenous genes has been successfully carried out (laenish et al1976) but never became a 
routine method of trans genesis mainly because of limitation of the size of the fragment that 
can be introduced into the retrovirus and of the high degree of mosaicism that results. 
Transgenesis by iontophoretic microinjection of DNA has been repot'ted(Lo 1983). This 
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method involves the use of an externally applied electric current to transfer DNA from the 
microinjection needle into the impaled one-cell embryo. Multiple integrations at several 
chromosomal sites without tandem insertions were obtained (Lo 1983). This method has 
the advantage of allowing the derivation of several lines of single-copy transgenic mice 
from one founder animal. Again, this method has never become a routine technique of 
transgenesis, maybe because of complicated experimental procedures. Sometimes very 
large DNA fragments need to be transferred into the mouse embryo, either because the 
gene of interest is very large or because a large amount of flanking DNA is needed to 
achieve proper regulation of the trans gene. These problems have been addressed by 
microinjection of a 250 kb yeast artificial chromosome (Schedl et at 1993) or of dissected 
human chromosome fragments more than 10 Mb in size (Richa et at 1989) into mouse 
embryos to produce transgenic mice. 
A tremendous step forward was achieved when gene replacement in transgenic mice was 
made possible (Thomas and Capecchi 1987, Capecchi 1989). To do this, a mutated copy 
of the gene is transfected into cultured embryonic stem (ES) cells. In some of the ES cells 
homologous recombination occurs. These cells can be enriched by antibiotic selection and 
identified by Southern blot analysis. When they are introduced into mouse blastocysts, 
they have the ability to colonise several tissues resulting in a chimaeric mouse. If the ES 
cells contributed to the germ line, some of the offspling of the founder chimaeric mouse 
would be entirely derived from the manipulated ES cell and would be heterozygous for the 
mutated copy of the gene. Homozygotes are then derived by breeding. In most instances 
the introduced gene contains an inactivating mutation so that homozygous null mutant 
(knock-out) mice are obtained. This technique has provided several useful animal models 
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for human diseases (for example Snouwaert et at 1992); it is very valuable when gene 
inactivation is needed. However it is too complicated for simple introduction of a foreign 
gene into the mouse genome, in which case microinjection of one-cell mouse emblyos is 
still the method of choice. 
Several thousands of transgenic mice with various genes have been reported. Here, some 
examples of transgenic mouse models of human diseases will be given and of the use of 
transgenic mice in understanding the molecular mechanisms of cancer will be briefly 
discussed. 
1.1.1 Transgenic mice and cancer 
The production of transgenic mice with several oncogenes including c-myc, H-ras, c-fos, 
SV40 large antigen and neu has been reviewed by Hanahan (1988 and 1989) and Adams 
and Cory (1991). The most striking findings of those studies can be summarised as: l. 
Overexpression of oncogenes deregulates cell proliferation. 2. Different oncognes are 
particularly influential on specific cell types. 3. Expression of the oncogene does not 
always result in immediate cell proliferation but requires time and probably cellular 
changes to elicit its effect (Hanahan 1989). Introduction of oncogenes into transgenic 
mice not only has provided increased knowledge on the mechanism of action of 
oncogenes, but has also resulted in animal models useful for testing therapeutic drugs 
(Dexter et at 1993). Animal models of lung, stomach, liver, breast, and prostate cancer 
have been produced (Sandmoller et at 1995, Greenberg et at 1995, Ullrich et at 1994, 
Dexter et aI1993). 
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1.1.2 Animal models of human diseases 
Examples of transgenic animal models of other human diseases are abundant in the 
literature. Mice carrying a transgene for a mutant form of human Cu, Zn superoxide 
dysmutase showed clinical and pathological features strikingly similar to the human familial 
amyotrophic lateral sclerosis (Dal Canto et al 1995). Transgenic mice overexpressing 
apolipoprotein A-ll developed atherosclerosis giving new insights into the role of composition .. 
and amount of high density lipoprotein in the development of atherosclerosis (Warden et at 
1993). Other transgenic mouse models of human diseases include sickle-cell anaemia (Trudel 
et al 1994), neurofibromatosis (Hinrichs et al 1987), lung fibrosis (Miyazaki et al 1995) 
and epidermolysis bullosa simplex (Vassar et a11991). This is not an exhaustive list of all 
the mouse models of human diseases but simply a selection of a few examples. 
Transgenic mouse models for cystic fibrosis represent a very good example of what 
transgenic animal models have to offer and also what their pitfalls are. Cystic fibrosis is 
the most common genetic disorder affecting Caucasians, for which there is no spontaneous 
animal model (Barinaga 1992) .. Transgenic animal models for cystic fibrosis have been 
produced by knock-out of the cystic fibrosis transmembrane conductance regulator 
(CFTR) gene by at least 3 independent groups (Snouwaert et al 1992, Dorin et al 1992, 
Hasty et al 1995). The null homozygous animals produced by Snouwaert et al (1992) 
showed a very reproducible phenotype characterised by death within 30 days of birth due 
to bowel obstruction. Even before the mice develop blockages, pathological changes in 
the intestines result in poor intestinal function, mimicking the intestinal symptoms in 
humans (Snouwaert et al 1992). Moreover, electro physiological studies on cells from the 
ailways and the intestinal tract of the knock-out mice showed abnermal chloride secretion, 
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again showing high similarity with the human disease (Clarke et al 1992). However, 
despite electro physiological abnormalities, the knock-out mice did not have mucus-
clogged lungs and lung infections which are characteristic of the human disease. In this 
regard, and because lung infections are the main cause of disability and death of cystic 
fibrosis patients, this particular model was partly disappointing. In the model developed 
by Dorin et al, the null homozygous mice were able to survive longer, developed focal 
lung lesions (Dorin et al 1992) and, when challenged with bacteria, showed susceptibility 
to lung infection with lesions similar to human cystic fibrosis (Davidson et al 1995). The 
longer survival of this model was due to residual low level of expression of the wild type 
CFfR caused by alternative RNA splicing (Dorinet alI994). 
Since they have been developed in 1992, the cystic fibrosis mouse models have been used 
to gain more insights into the pathological changes that lead to the disease and to test 
potential therapies. Valverde et al (1995) showed that the intestinal cells of the cystic 
fibrosis mice have an impaired cell volume regulation function. For the first time, an effect 
on cell function of the chloride transport deficiency associated with the CFTR defect was 
found, even though its relevance to the disease was not clear. Zhou et al (1994) 
transferred an intact CFfR gene under the control of an intestine-specific promoter to 
CFTR (-) mice by pronuclear microinjeetion of one-cell embryos, and showed correction 
of the electrophysiological defect and survival of the mice. This experiment demonstrated 
the feasibility of CFTR gene replacement therapy. The mouse models were also used to 
test the efficiency of adenovirus-mediated and liposome-mediated somatic transfer of wild-
type CFTR gene to the airways (Grubb et al 1994, Hyde et al 1993) and showed partial 
correction of the ion transport defect. Thus, the CFfR mouse model was a highly 
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successful one. It developed disease similar to human cystic fibrosis and was used to 
better understand the pathophysiology of the disease and to test potential therapies. 
At the other end of the success spectrum is an attempt to generate a mouse model for 
Lesch-'Nyhan disease by knocking out the hypoxanthine guanine phosphoribosyl 
transferase (HPRT) gene. The mice had no symptoms at all,- because they had another 
enzyme that could cover for the missing HPRT (Hooper et alI987). 
1.2 Tissue-specific promoters 
In most instances, generation of transgenic mice involves introduction into the mouse 
genome of a recombinant molecule that consists of the coding sequence of a particular 
gene linked to the promoter of another one, so that the genes of interest can be expressed 
in ectopic tissues. In the case of mouse trans genesis, the term promoter is generally used 
in the large sense and means the DNA sequence 5' from the coding region necessary to 
direct gene expression to a particular tissue. For the purpose of transgenesis, several 
mouse organ-specific promoters have been identified, including the mammary gland-
specific rat p-casein promoter (Lee et al 1989), the liver-specific albumin promoter 
(Pinkert et al 1987), the pancreas-specific insulin promoter (Fromont-racine et al 1990), 
and many others. 
1.3 The rabbituteroglobin promoter 
Utero globin (UG) constitutes 40 to 60% of the rabbit uterine fluid on day 5 of pregnancy 
(Beier, 1968). It has been extensively studied as a model for variation of the uterine fluid 
protein content under the action of steroid hormones. UG has been purified to 
homogeneity from washings of pregnant and progesterone-treated rabbit uteri (Fridlansky 
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and Milgrom 1976). It is composed of 2 identical subunits of 70 amino acids of a 
molecular weight of about 8 000 held together by disulfide bonds and other noncovalent 
bonds. UO binds progesterone specifically (Beato and Baier 1975). Its function is 
unknown but, because of the timing of its expression, it was thought to play a role in 
embryo implantation in the rabbit (Krishnan et al 1967). Analysis of its amino acid 
sequence has revealed a similarity with inhibitors of phospholipase-A2, suggesting an anti-
inflammatory role (Miele et al1988) . 
While the main site of expression of UO is the uterus, the protein has also been found in 
the lungs, where its expression is constitutive and weak, as well as in the oviduct, the male 
genital tract, and the oesophagus of rabbits (Aumuller et at 1985, Ooswami and Feigelson 
1975). Histological examination showed that expression of UO in these tissues was 
restricted to the epithelial cells (reviewed by Beato et al 1983) In the lungs, UO is 
expressed in the non-ciliated bronchial cells called Clara cells (Au muller et al 1985). 
Initially it was thought that UO was a protein unique to the rabbit. However UO-like 
proteins were later found in rat prostate (Aumuller et al 1985) and lungs (Lopez de Haro 
et al 1988a), and in human utems (Cowan et al 1986) and prostate (Manyak et al 1988). 
This was confinned by the cloning and sequencing of the genes coding for the rat 
polychlorobiphenyl-binding protein (Nordlund-MolIeret al 1990) and the human Clara cell 
protein (Singh et al 1990) genes. These proteins showed 53% and 61 % similarity to UO, 
respectively, and are encoded by the same gene which was later named CClO. The mouse 
CClO has also been cloned (Margraf et al 1993). The pattern of expression of CClO is 
different from that of UO. While UO is expressed strongly in the utems and weakly in the 
lungs of rabbits, the main site of expression of CClO is the lung (Margraf et at 1993). 
lO 
Expression of UG is regulated by steroids. In the rabbit uterus, expression is stimulated by 
progesterone (Shen et al 1983) while in the male genital tract, it is induced by androgens 
(Lopez de Haro et al 1988b). In the lungs, expression of UG is constitutive (Savouret et 
al1980) or weakly up-regulated by glucocorticoids (Lombardero et alI981). 
The UG gene has been cloned had characterised. It is a single gene composed of 3 exons 
separated by 2 introns (Snead et al 1981). DNAse I hypersensitivity studies and steroid 
receptor binding experiments have shown that the 5' flanking region contains progesterone 
and glucocorticoid receptor binding sites about 2.6 kb upstream from the transcription 
start site (Cato et al1984, Jantzen et alI987). 
To detelmine the location of the cis-acting elements that control the expression of the UG 
gene, DeMayo et al (1991a) produced transgenic mice with genomic fragments containing the 
UG coding sequence and various amounts of 5' flanking sequence ranging from 0.6 to 3 kb 
(UG3.0, UG2.3 and UGO.6). Expression in the lung and uterus was observed with all 
constructs, but was weak and variable with UGO.6. UG expression in the lungs of UG3.0 and 
UG2.3 mice was weakly stimulated by treatment with dexamethasone but the increase was 
minimal-and not as strong as the increase of expression of the endogenous CCIO after 
treatment with dexamethasone (DeMayo etalI991a). Expressionin the uterus was weak: and 
variable with 6 out of 10 lines of transgenic mice expressing the transgene. The strongest 
uterine expression was observed with UG3.0. In the one line examined, expression of UG in 
the uterus was about 2.5 times higher in transgenic mice treated with a regimen of estrogen and 
progesterone than in control mice: These results demonstrate that 600 bp of UG 5' flanking 
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DNA is sufficient to direct-weak: expression of va to the lungs and utelUs of transgenic mice 
but at least 2.3 kb are needed for strong expression in the lung. However, other cis acting 
elements are required for full expression in the utelUS. The 3 kb of 5' flanking region contain 
some of the elements necessary for steroid regulation in the lung and the utelUs but other 
elements are needed (DeMayo et aI1991a). 
In view of these results, a cloned genomic fragment containing 3.3 kb of ua 5' flanking DNA 
has been used to direct expression of heterologous genes to the lungs of transgenic mice 
(DeMayo et aI1991b). 
A fusion gene consisting of the U03.3 promoter and the large T-antigen gene of the SV40 
virus was used to produce transgenic mice. Eleven founder animals (5 female and 6 male) were 
generated of which seven developed bronchoalveolar neoplasms. Four of the founder males 
also developed primitive undifferentiated urogenital tract tumours. One founder female and 
one female offspring ofa founder male developed glandular para-ovarian tumours. The 
predominant site of trans gene expression was the lung (DeMayo et al 1991b). Others have 
used 4.7 kb of the rabbit UO 5' flanking sequence to express the SV40 T-antigen in transgenic 
mice. All transgenic founders developed bronchoalveolar adenocarcinomas, probably due to 
the expression of transgene in Clara cells. Most founders also developed tumours of the 
submandibular salivary gland and of the stomach. Adenocarcinomas of the genital tract were 
found in one male and one female founder. One line of transgenic mice was established. 
Transgenic descendants developed lung adenocarcinomas and, depending on the genetic 
background, tumours of the stomach, the salivary gland, the pancreas, and, sporadically, 
tumours of the prostate, the utelUs and the oviduct (Sandmoller et al 1994) .. These results 
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prompted the -authors to more closely examine the site of expression of endogenous and 
transgenic UO. Both were found to be expressed in the serous cells of the submandibular gland 
and in the pepsinogen cells of the gastric epithelium, whereas expression in the pancreas has not 
been investigated (Sandmoller et alI994). Expression in the stomach was not irivestigated by 
DeMayo et al (l991a and 1991b) whereas expression in the salivary gland was not found. It is 
likely therefore, that the additional 1 kb of 5' flanking sequence used by Sandmoller et al 
contains the cis-acting elements necessary for targeting expression to the stomach and salivary 
gland. 
Transgenic mice expressing the human growth hormone (hOH) gene under the control of the 
U03.3 promoter were produced to get more insights into the time and location of expression 
of UO-driven transgenes (Margraf et al 1993). hOH was chosen because it is not normally 
expressed in the lung and because of the availability of good antibodies that make 
immunohistochemical detection relatively easy. Abundant hOH mRNA was detected in the 
lungs of transgenic animals. The transgene was also weakly expressed in the uterus, ovary, 
and epididymis. Stomach and salivary glands were not investigated. Immunoelectron 
microscopy demonstrated that the site of lung expression was the Clara cell. The trans gene 
was initially detectable on day 16 of gestation. 
1.4 Emphysema 
1.4.1 The elastase-anti elastase equilibrium and the aetiology of emphysema 
Emphysema has been defined as a condition of the lung characterised by abnormal permanent 
enlargement of air spaces distal: to the terminal bronchioles accompanied by destruction of the 
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walls without obvious fibrosis (Snider et al 1985). The two most common causes of 
emphysema are cigarette smoking (Janoff et al 1983) and genetic deficiency in ai-antitrypsin 
(Laurell et al 1963). In both cases, disruption of the elastase-antielastase equilibrium in the 
lungs is believed to playa key role in the aetiology of emphysema (Janoff et alI986). 
The proteinase-anti proteinase imbalance theory came essentially from2 lines of evidence. First 
Laurell and Eriksson (1963) showed low levels of alpha-I-antitrypsin in patients with early 
onset emphysema. Second, several experiments involving instillation of proteases, such as 
papain (Gross et al1964) and pancreatic or neutrophil elastase (Snider et al1986), in the lungs 
of experimental animals resulted in acute inflanunatory lesions followed by progressive lesions 
that mimic emphysema. The emphysematous lesions were observed only when elastolytic 
enzymes were used (Snider et al1986). 
More evidence that degradation of elastin is central to the development of emphysema came 
from experiments where the elastin digestion by-products were measured. Elastin-derived 
peptides were found to be elevated in the serum of smoking patients with- emphysema as 
opposed to healthy non-smokers, while healthy smokers had an intennediate level (Kucich et al 
1985). Immunohistochemistry of lung tissue from emphysematous smokers revealed elastase 
immunoreactivity associated with elastic fibres in the lung interstitium that correlates with the 
severity of emphysema, whereas immunoreactivity was negligible in healthy patients (Damiano 
et al1986). 
The most abundant antiproteinase in the lung epithelial fluid is alpha-I-antitrypsin (AA T) 
(Gadek et al198I). AAT binds human neutrophil elastase (HNE) invitro and in vivo to fonn 
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an essentially irreversible complex "(Beatty et al 1980). While AATha~ been considered the 
main protein in the elastase-antielastase theory, secretory leucocyte proteinase inhibitor 
(SLPI), another protease inhibitor, has recently attracted much attention. SLPI is produced by 
the non-ciliated bronchial epithelial cells (Franken et al 1989), fonTIS stable complexes with 
HNE (Gauthier et al1982), inhibits elastin"bound HNE(Gauthieret aZ 1982), and because of 
its small molecular weight, can readily access the lung interstitium ..... Despite its -low 
concentration in epithelial lining fluid (Gadek et al1981), SLPI may playa role in the elastase-
antielastase balance. 
Cigarette smoking results in an accumulation of neutrophils (Kilburn et aZ 1975, Hunninghake 
et aZ1983) and macro phages (Matulionis 1979) in the alveolar spaces. Continuous high levels 
of elastase secreted from the neutrophils overwhelm the inhibitory effect of antielastase 
(aI-antitrypsin) and result in the progressive destruction of the lung connective tissue (Janoff et 
al1986). Also cigarette smoke has a damaging effect on AAT which results in a decrease of 
its elastase binding capability. Similarly, aI-antitrypsin deficiency allows proteolysis that results 
in tissue destruction despite normal levels of elastase. 
Although the elastase-antielastase eqUilibrium is the most attractive theory because it explains 
most observations related to emphysema, studies from experimental emphysema have shown 
that itmay not be the only mechanism (Gordon et al, 1994). There is mounting evidence that 
macro phages as well as neutrophils are involved in the development of the disease which means 
that metalloproteases are also involved in the process (Gordon et aZ, 1994). 
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1.4.2 Animal models of emphysema 
Several animal models of emphysema have been designed and used for several purposes, 
including gaining more insight into the elastase-antielastase theory, testing the role in the 
aetiology of emphysema of certain agents identified by epidemiological studies, and testing the 
effect of antielastase agents on the development of the disease (Snider et aI1986). To induce 
emphysema, most workers instil porcine pancreatic· elastase into the trachea of hamsters 
(Snider et at 1986). This results in localised acute destruction of lung tissue in a matter of 
hours following the instillation of elastase (Snider et al 1986), followed 3 to 6 weeks later by 
more progressive lesions that mimic human emphysema. Other elastolytic agents that have 
been used to induce emphysema in laboratory animals include papain (Snider et al 1986), 
human neutrophil elastase (Janoff et al 1977), and neutrophil proteinase 3 (Kao et at 1988). 
Apart from hamsters, rats, dogs and mice have been used. At present, it is not clear which 
model is the best. Probably, the choice of the model for a given experiment would depend on 
the particular question the experiment is seeking to answer. 
Two genetic mouse models for emphysema have been described. The blotchy mouse (Rang a et 
at 1983) and the tight-skin mouse (Szapiel et at 1984) develop lesions that mimic human 
emphysema. However, these lesions are the result of collagen defects rather than imbalance 
between elastase and anti-elastase and, therefore, these animals are not useful for testing 
elastase inhibitors designed for .therapeutic use. During the course of this work, the pallid 
mouse, a mouse model that mimics the human condition more closely has been described 
(Mrutorana et al 1993). The pallid mouse develops emphysema at advanced age (12 months 
onwards) as a result of inborn deficiency in a.1-antitrypsin. The model is in agreement with the 
elastase-antielastase theory, but because the lesions are mild and slow to develop, it may have 
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limited use for drug testing. To our knowledge, since the description of emphysema in the 
pallid mouse, there has been no published work on the use of this mouse to test therapies or 
advance knowledge on the mechanism of emphysema. 
A transgenic mouse expressing collagenase has also been shown to develop emphysema 
(D'Amiento et al 1992). This suggests that proteases other than elastase may have a central 
role in the pathogenesis of the disease. This model has the advantage of challenging the 
established theory on the development of emphysema and bdngs up the possibility that other 
causative agents may be involved. However until the relationship of these causative agents to 
emphysema is firmly established, the collagenase mouse is of little use. 
1.5 Lung cancer 
1.5.1 Incidence and prognosis 
Lung cancer is a major health problem. It is the leading cause of cancer death in men and the 
third cause of cancer death in women, after breast and bowel cancer. The latest statistics 
available show that in New Zealand in 1992, there were 990 new cases of lung cancer in men 
and 516 cases in women. Those represented 16% of all cancers in men and 9% in women. In 
- 1992, there were 947 deaths caused by lung cancer in men and 445 in women. This closeness 
of the figures for incidence and death by lung cancer shows how poor the prognosis of patients 
with lung cancer is. In the last 5 years, a decrease in the overall incidence of lung cancer has 
been observed with the gap between men and women narrowing, probably due to the fact that 
there are more female and less male smokers (Johnson 1995). At the time of diagnosis only 
20% of all lung cancer patients -will have localised disease, while the others will have 
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dissemination to the lymph nodes or distant metastases. Even in patients with localised disease, 
the 5-year survival rate is only 30% in men and 50% in women. Most patients die within one 
year of diagnosis (Minna 1991). 
1;5.2 Histology and treatment 
Lung cancers are classified as small cell and non-small cell, which include adenocarcinoma, 
epidermoid and large cell carcinomas. This classification as small cell and non-small cell is 
made on the basis of different clinical management and prognosis. At the time of diagnosis, 
small cell carcinomas are usually disseminated and are treated with chemotherapy with or 
without radiotherapy, with a 5-year survival rate of less than 1%. In contrast, non-small cell 
carcinomas are often localised at the time of diagnosis and surgical resection can be attempted 
in those cases with or without radiotherapy. Non-operable patients are treated with 
radiotherapy, and if the cancer is disseminated outside the chest, by chemotherapy. The 5-year 
survival rate after curative resection of non-small cell carcinomas varies from 27% to 37% 
(Minna 1991). 
1.5.3 Aetiology 
The majority of lung cancer is caused by carcinogens and tumour promoters inhaled during 
cigarette smoking. There is a dose-response relationship between the lung cancer death rate 
and the number of cigarettes smoked in a lifetime (Minna 1991). While there is no known 
genetic predisposition to lung cancer, several genetic mutations have been documented in 
human lung tumours, including point mutations of ras (Rodenhuis et al 1987), gene 
amplification or overexpression of myc (Little et al 1983) and erb B (Berger et al1987), and 
point mutations of the tumour suppressor genes Rb (Harbour et al1988) and p53 (Takahashi 
18 
et al 1989); Other canqidate-genesincluderaf,jun;-src, retinoic acid receptorand phosphatases 
(reviewed by Birrer and Brown, 1992). ras gene mutations occur in 15 to 30 % of human non-
small cell lung cancers most of which are adenocarcinomas but not in small cell lung cancer 
(Birrer and Brown 1992). Most ras mutations occur in K-ras (Mitsudomi et alI991). 
1.5.4 Gene therapy 
Because the prognosis of lung cancer is so poor, novel treatment protocols along with tools for 
earlier diagnosis are needed. Both will probably come from the massive amount of new 
··information acquired in recent years about the genetic changes that occur in·cancer. Gene 
therapy is a promising therapeutic alternative that may result in a significant improvement of the 
prognosis of lung cancer patients. Several approaches to gene therapy of cancer in general are 
being investigated and may eventually be used with human lung cancer. Inactivation of an 
oncogene is one approach, with a prime target being ras. Clinical trials where a retrovirus 
encoding an antisense ras RNA is transferred to lung tumours have been approved by the 
United States Federal DNA advisory committee (Chelfas 1992). Transfer .of a wild-type 
tumour suppressor gene may restore lost function to cancer cells and revert them to normal 
phenotype. Clinical trials involving retrovirus-mediated p53 transfer to lung tumours have also 
been approved (Cherfas 1992). Selective transfer of a toxic gene to tumour cells but not to 
norma1cells may result in selective killing of cancer cells. Cells producing Rretrovirus carrying 
a thymidine kinase gene have been injected into the brain -of rats harbouring experimental 
glioblastomas. Because retroviruses selectively infect dividing cells, only tumour cells were 
infected and expressed thymidine kinase. The rats were then given ganciclovir, which is 
converted into a toxic compound by thymidine kinase, resulting in eradication of the tumours 
(Culver et alI992). Others have attempted to stimulate the immunogenicity of cancer cells by 
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transfecting them with cytokines (Apte et al 1992) or other cell surface regulatory antigens 
such as B7 (Townsend et al 1993) and obtained partial reduction of tumour burden in nude 
mice grafted with transfected tumour cells compared with those grafted with intact cells. The 
main challenge of gene therapy of cancer is to be able to transfect all tumour cells without 
harming the normal cells. If not all cancer cells are targeted by the therapeutic agent, those left 
behind will regrow and result in a cancer relapse. Currently, despite very intensive research and 
development efforts, there is no vector that can result in the transfection of all cells in a tumour. 
1.5.5 The AlJ mouse: an animal model for lung cancer 
The NJ mouse offers an experimental model that has been extensively used for 
carcinogenesis studies (Stoner and Shimkin 1985). These mice are susceptible to lung 
cancer, with the majority of animals developing lung adenomas by the age of 18 months 
(Stoner and Shimkin 1985). The tumours can also be induced by various chemicals. A 
single injection of 20 mg ethyl carbamate at 6 weeks of age will induce the development 
on average of 24 lung adenomas per mouse after 16 weeks, some of which may progress 
to adenocarcinomas after 8 months (Taete et al 1987). Figure 1.1 shows one lobe from 
the lung of a mouse 16 weeks after ethyl carbamate injection, with 3 visible tumours on 
the surface. Genetic changes in these tumours include ras mutations, which occur in 
nearly all tumours, as well as a reduced expression of the Rb tumour suppressor gene and 
overexpression of the myc oncogene (Re et al 1992). 
1.5.5.1 Cellular origin of the mouse lung tumours 
The cellular origin of the tumours has been controversial since they were first described 
(Livingood 1896). It is still not clear whether the tumours in the NJ mouse arise from 
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alveolar type 2 cells (the alveolar cells that produce surfactant) or the Clara cells (the 
bronchial non-ciliated cells) or from both. Also, it is not clear whether one type of 
carcinogen is more likely to induce preferentially tumours from one kind of cell. 
After the first description of mouse lung adenomas, there were several reports describing 
the tumours as either papillary or infiltrative tumours of cuboidal epithelium (Tyzzer 1909, 
Jobling 1910, Haaland 1911, Slye et al 1914). Based on those observations, it was 
proposed that adenomas originate from both the bronchial and alveolar epithelium (Jobling 
1910, Slye et al 1914). However, observation of early pathogenesis in mice 1- to 11-
weeks old concluded that the tumours were arising from the alveolar epithelium (Grady 
and Stewart 1940). This study, as well as later ultrastructural identification of type 2 cells 
in adenomas (Brooks 1968), almost resulted in a consensus among investigators as to the 
alveolar origin of adenomas (Shimkin and Stoner 1975). 
The agreement was not complete, though. Mori (1964a, 1964b) demonstrated that 56% 
of 4-nitroquinoline-induced adenomas originated from between terminal bronchioles and 
alveolar ducts and ascribed approximately half of them to neoplastic bronchial epithelium. 
Similarly, Amaral-Mendez (1969) proposed that papillary tumours arise from both alveolar 
and bronchial epithelium. The conclusions of all those studies were based on histological 
features and are open to challenge given the inevitable degree of SUbjectivity in the 
interpretation of the histology. 
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Figure 1.1: NJ mouse lung 16 weeks after injection with ethyl carbamate viewed 
under a dissecting microscope at lOX magnification. The arrows show 
three adenomas 
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When it was discovered-by electron microscopy studies that one type of human peripheral 
adenocarcinoma arose from Clara cells, based on similar ultrastructural features (Montes 
et al 1966), there was a renewed interest in the NJ mouse. In the late 1970s, it was 
proposed that the 2 histologically distinct tumours arise from different cells. Electron 
microscopy studies suggested that the papillary tumours arise from Clara cells whereas 
alveolar tumours originate from type 2 cells (Kauffman et al 1979). Scanning microscopy 
(Sato et al 1980) showed that the 2 adenomas have distinct surface features, in which 
tumour surfaces more nearly resemble their tissue of origin than one another. Others have 
concluded, however, that the papillary tumours are derived from the alveolar tumours and 
represent a more advanced stage of cancer development (Kimura 1971). The results of 
Kimura are in contrast with those of Kauffman (1981) who found no difference between 
the proportions of alveolar and papillary tumours in the beginning and at the end of a 6~ 
month period, supporting the concept that alveolar and papillary tumours arise from 
different cell lines. 
Strain differences in the proportions of each type of tumour were found: NJ mice had 
14% papillary adenomas, whereas the proportion in other strains varied from 13 to 68 % 
(Beer and Malkinson 1985). 
In an attempt to find a marker for each type of tumour, Beer and Malkinson (1984) 
examined the localisation of eH]dexamethasone in urethane-induced mouse lung tumours 
and found strong nuclear binding in the nucleus of papillary but very little binding in 
alveolar tumours. Binding was strong in larger papillary and anaplastic tumours 
suggesting that malignant tumours arise from papillary tumours which are derived from the 
Clara cells. This is also supported by the observation of papillary structures mixed with 
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. adenocarcinomas, and by progression to malignancy of transplanted papillary tumours 
(Kauffman 1981). In conclusion, the cellular origin of mouse lung tumours remains 
unclear. 
1.6Ras 
The ras genes (H-, K-,. and N-ras) encode an evolutionarily conserved family of highly similar 
proteins with molecular weight of 21,000 that is widely present in eukaryotic cells (Barbacid 
1987). These proteins are located in the inner side of the cell membrane, bind GTP and GOP 
and have a GTPase activity (Barbacid 1987). Ras plays a central role in transmitting signals 
from receptors at the plasma membrane to the nucleus, thereby regulating cell growth and 
differentiation. The ras protein possesses an active form which isGTP-bound and an inactive 
form which is GOP-bound. After stimulation by various factors, the ras protein becomes 
activated, transduces the signal to effector molecules and goes back to the inactivated state 
(Bos 1989). 
Several components of the ras signal transduction pathway have recently been identified 
(Figure 1.2). While several pathways leading to ras have been found (Feig 1993), the best 
characterised is the one linking a tyrosine kinase receptor to ras (Skolnik et al 1993). Binding 
of the specific ligand to a tyrosine kinase membrane receptor (for example binding of insulin to 
the insulin receptor) results in auto-phosphorylation of the receptor which in tum induces 
binding of GRB2 to the receptor. GRB2 binds Sos which binds ras. Sos is a ras exchange 
factor and, when it binds to ras, it induces the exchange of the ras-bound GOP for a GTP. 
Binding of GTP activates ras. Activated ras probably transmits its signal to a variety of 
molecules, one of which is raf (Avruch et alI994). Ras activates raf by bringing it to the inner 
side of the plasma membrane (Leevers et al 1994). The subsequent steps of protein activation 
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-- involve MEK, MAP kinase kinase, and MAP kinase. MAP kinase is a nuclear protein which 
phosphorylates transcription factors and regulates inflammatory mediators and the cytoskeleton 
(Avruch et al 1994). After transmitting the signal, the intrinsic GTPase activity of ras will 
hydrolyse ras-bound GTP into GDP, thereby returning ras to an inactive state (Barbacid 1987). 
The GTPase activity of ras can be stimulated by a GTPase-activating protein or GAP (WigleI' 
1990). The role of GAP is not very clear as, in addition to stimulating the GTPase activity of 
ras, GAP may 
also be an effector molecule of ras as suggested by its binding to the effector domain of ras 
(Adari et al1988). 
Substitutions or deletions at many sites on ras between amino acids 26 and 48 result in loss of 
its mitotic activity without any effect on its GTPase activity or its membrane localisation: 
Crystallography analysis showed that ras residues 31-38 were situated on a loop whose 
confonnation changed significantly, depending on whether the bound nucleotide was GTP or 
GDP. This region was therefore considered as essential to the mitogenic signalling and was 
suspected to bind the downstream effector of ras (Marshall 1993); it was named the effector 
domain. Later experiments showed that raf and GAP bind ras at the effector domain (Adari et 
al1988, Zhang et all993). 
Mutated ras genes were initially identified by their ability to transfonn NIHl3T3 cells (Barbacid 
1987). Subsequently, a variety of tumours was found to harbour ras genes having mutations in 
codons 12, 13 and 61 (Bos 1989). The resulting mutated ras proteins are pennanently in the 
activated fonn and can therefore stimulate growth autonomously. ras mutations are common 
features of human cancer, with an incidence as high as 90% in adenocarcinomas of the pancreali 
(Bos 1989). 
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There is some correlation between tumour type and ras gene mutation. For example in lung 
adenocarcinoma, mutations occur essentially in K-ras whereas in myeloid leukemia they occur 
in N-ras (Bos 1989). Ras mutations have clinical implication in tennsof diagnosis, prognosis 
and treatment of human cancer. Sidransky and co-workers (1992) have shown that it is 
possible to detect ras mutations in the stools of patients with early colorectal tumours, allowing 
early diagnosis and better prognosis. N-ras mutations in childhood acute leukemia (Lubbert et 
al 1990) and K-ras mutations in lung adenocarcinomas (Rodenhuis and Slebos 1992) are 
associated with poor prognosis. 
The large amount of knowledge gathered about the involvement of ras in lung cancer will 
eventually lead to a better treatment. Some experiments in tissue culture and in laboratory 
animals have already shown promise. Transfection of a human lung cancer cell line 
homozygous for a K-ras mutation with a plasmid that synthesises an antisense K-ras mRNA 
resulted in a significant growth inhibition when the cells were cultured in vitro and injected into 
nude mice (Mukhopadhyay et al1991). Similarly, the neoplastic phenotype of cultured tumour 
cells expressing a mutant H-ras was reversed in tissue culture after adenoviral-mediated 
delivery of an anti-ras ribozyrne designed to cleave the mutant sequence in codon 12 of the 
activated H-ras (Feng et al 1995). 
1.7 Tumour suppressor genes 
In the last few years, interest in tumour suppressor genes has been growing exponentially. 
The growing list includes tumour suppressor genes such as Rb, p53, WT-l, DCC, NF-l, 
p16, APe , VHL, and BRCAI (Bertelsen et al 1995) which have been proven to 
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-contribute to the carcinogenesis- of human cancers (Reviewed by Bertelsen et al 1995). 
Suspected tumour suppressor genes include Krev-1 (Kitayama et al 1989) and lysyl 
oxidase (Contente et alI990), which, despite demonstrating tumour suppressor activity in 
tissue culture, have not as yet been clearly associated with any human cancer. Loss or 
inactivation of tumour suppressor genes contributes to the-generation of a fully cancerous 
state (Bertelsen et al1995). 
1.7.1 Mechanism of action of tumour suppressor genes 
The precise mechanism by which these genes suppress cell growth is not completely 
elucidated. WT-l, Rb, BRCA1, and p53 (Bertelsen et al 1995) are nuclear proteins and 
function as transcription factors. NF-l codes for a GTPase-activating protein and 
therefore may suppress growth by interfering with the ras pathway (Bertelsen et al 1995). 
The product of DCC is a cell surface protein related to adhesion molecules that regulate 
cell behaviour through interactions with other cells (Bertelsen et al 1995). p53, one of the 
most studied tumour suppressor genes, suppresses cell growth by turning on the gene for a 
21-Kd protein that blocks Cdk enzymes and thus cell division (Marx 1993). p53 also 
functions by inducing DNA repair in response to DNA damage (for example by radiation), 
or by inducing apoptosis if the DNA is damaged beyond repair (Lowe et alI993). 
1.7.2 Krev-l 
Krev-l was identified as a negative regulator of ras. While several molecules that 
stimulate ras have been identified, only a few down-regulators have been identifIed. To 
look for the latter, Noda et al (1989) transfected a ras-transformed NIHJ3T3 cell line (DT) 
with a human skin fibroblast cDNA expression library and looked for revertant clones. 
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One of the revertant clones containedKrev-l (K-ras revertant One). The gene was cloned 
and sequenced and further investigated for tumour suppressor properties by transfecting 
DT cells with a plasmid coding for Krev-l (Kitayama et al 1989). The reversion 
percentage of DT cells expressing transfected Krev-l was relatively low, with 2.3 to 4.7 % 
of the neomycin-resistant colonies having a flat morphology, indicating reversion, and 29% 
partially flat (Kitayama et al 1989, Zhang et alI990); The 3 types (flat,- partially flat or 
transformed) of Krev-l transfected cells had a growth rate lower than the DT control cells 
and had a reduced colony-forming ability in soft agar (Kitayama et al 1989). The degree 
of reversion depended on the level of Krev-l mRNA expression, with the reverted cells 
showing the highest level of expression and the transformed cells the lowest (Kitayama et 
aI1989). Amino acid substitutions in the Krev-l protein at specific codons (12 Gly to Val 
or 63 Gin to Glu) potentiated its tumour suppressor activity, with the codon 63 mutation 
having the strongest effect (Kitayama et al 1990). Krev-l is specific to ras as it does not 
revert cells transformed by other oncogenes (eg. src, fos) (Kitayama et aI1989). 
Krev-l and ras have a 50% identity at the protein level, with the region corresponding to 
the effector domain of ras being the most conserved (Kitayama et at 1989). This 
homology and the correlation between the expression of Krev-l and the degree of 
reversion in transfected cells led to the hypothesis that Krev-l antagonises the action of ras 
by competing for a common target. Support for this theory came from the findings that 
Krev-l protein forms an inactive complex with rasGAP (Fresh et al 1990), and binds raf 
(Ruggieri et al 1994), both of which may be effector molecules for ras (Zhang et al 1993, 
Adari et alI988). 
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Limited -data are available-on- the role of Krev-lin -human cancer. Reduced Krev-l 
expresslOn was found in various sarcomas (rhabdomyosarcoma, fibrosarcoma, 
chondrosarcoma, histiocytoma) and in adenocarcinoma of the salivary gland (Culine et al 
1990). These findings suggest that down-regulation of Krev-l plays a role in the 
development of these cancers but,given the technical difficulties of accurately quantifying 
RNA in tumours and normal control specimens, could be challenged. Loss of 
heterozygosity of a Bel I-polymorphism has been documented in only lout of 18 colon 
adenocarcinomas, suggesting that gross loss of the Krev-l gene is a rare event in colon 
cancer (Young et alI992). 
Inoculation into nude mice of a human non-small-cell lung carcinoma cell line (Calu-6) 
transfected with Krev-l resulted in a 50% decrease in tumour incidence compared with 
non-transfected cells, as well as a reduction in tumour size (Caarnano et al 1992). This 
tumour suppressor effect, however, was not seen when Krev-l was transfected into 3 
other human tumour cell lines that also express an activated rasoncogene(Sato et al 
1994). This discrepancy remains unexplained and strengthens the case for further 
investigation of the properties of Krev-l as a tumour suppressor gene, which have not 
been demonstrated in vivo. 
1.8 Summary 
Transgenic mouse models can provide insights into the pathophysiology of human diseases 
and can be used to test potential therapies. Because of our experience with the va 
promoter, which directs expression of heterologous genes specifically to the lungs of 
transgenic mice, we have chosen to produce models of human lung diseases. The first 
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-- modelis for emphysema. There is a need for such a model to -study potential therapies and 
currently available models are not completely satisfactory. Also the elastase-antielastase 
theory on the development of human emphysema is in need of more investigation and a 
transgenic mouse model may give more ground to it. The second model is intended to 
provide a system for testing the effect of putative tumour suppressor genes on lung cancer 
in vivo. The system takes advantage of the availability of theN] mouse strain,a highly 
predictable and manipulable model of human lung adenocarcinoma and of the ability of the 
va promoter to direct expression of heterologous genes to the lungs. The system was 
used to investigate the activity of the putative tumour suppressor gene Krev-l in vivo. 
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Materials used are listed in Appendix 2. 
Chapter 2. 
Methods 
2.1 Construction of recombinant plasmids 
Restriction digestion of plasmids was typically carried out using 2 J-tl 10 X reaction buffer 
supplied by the manufacturer and IOU enzyme in a reaction volume of 20 J-tl incubated at 
37°C for 1 to 12 hours .. One J-tl of the digested DNA was run in a 0.8 % agarose gel in 
0.09 M Tris, 0.09 M boric acid, 0.002 M EDTA (TBE) with 0.5 J-tg/ml ethidium bromide 
to verify that the reaction had gone to completion. 
Dephosphorylation of DNA ends was carried out by adding 1 J-tl (1 unit) calf thymus 
alkaline phosphatase and 2 J-tl 10 X reaction buffer (supplied by the enzyme's manufacturer) 
to the restriction digestion mixture and incubation at 45°C for one hour, followed by heat 
inactivation of the enzyme at 65°C and phenol-chloroform extraction and ethanol 
precipitation. 
Isolation of a DNA fragment after restriction digestion was carried out by running the 
digestion mixture ina 0.8% agarose gel in TBE then purifying the fragment of interest from 
the gel either by electrophoresis onto DEAE-paper (Sambrook et al 1989) or using glass 
milk (GeneClean or GlassMass kits) according to the manufacturers' instructions. 
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End-'filling was performed in a reaction -with 1 Ilg DNA and 2 Uof Klenow-DNA 
polymerase I in 25 III nick translation buffer (Sambrook et al 1989) containing 2 mM each 
of the 4 dNTPs. After incubation at room temperature for 30 min, the mixture was heated 
to 80°C for 20 min and the DNA extracted with phenol:chloroform (1: 1), then precipitated 
in 2 M ammonium acetate with ice-cold ethanol. 
DNA ligations were carried out in a total volume of 10 Jll containing 1.0 U T4 DNA ligase 
in 66 mM Tris-HCl pH 7.5,5 mM MgCh, 1 mM DTT, 1 mM ATP. The ligation mixture 
was incubated overnight at room temperature for blunt-end ligation and at 15°C for sticky-
end ligation. The amount of DNA depended on the size of the fragments to be ligated and 
the molar ratio of vector to insert was 1 to 3. 
DH5a cells were made competent using the calcium chloride method (Ausubel et al 1987). 
One to five JlI of ligation mixture were used to transform competent cells, essentially as 
described by Hanahan (1983). The cells were spread on Luria Broth (LB) agar plates 
containing 100 Jlg/ml ampicillin, 50 JlI 100 mM isopropylthiogalactoside and 20 Jll 20 
mg/ml X-Gal, and incubated at 37°C overnight. Supercoiled pUC18 was used as a positive 
control and to test the efficiency of transformation of the competent cells. 
Individual colonies were picked from the agar plates and-grown overnight in 10 ml LB broth 
containing 50 Jlg/ml ampicillin. Plasmid DNA was extracted and purified with "Magic 
Minipreps" columns according to the manufacturer's instructions. 
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2.2 Constructs 
2.2.1 Construction of plasmid pUGHNE 
A plasmid (pUGHNE) containing UG promoter elements ligated to HNE genomic DNA was 
constructed by cloning a 4.7-kb genomic HNE fragment containing the entire HNE gene and 
100 bp of promoter region (5' to the cap site) 3' to a UG genomic fragment containing 3.3 kb of 
promoter region and 7 base pairs of 5' untranslated region of the utero globin gene (Figure 2.1 , 
Snead et al1981). In a frrst step pUG3.3 was constructed. To do this, pUG 11.8, which consists 
of a genomic DNA fragment containing the entire UG gene cloned in the CIa I site of 
pBR 322 was digested with Eco Rl, a 5-kb DNA fragment isolated from an agarose gel and 
cloned into the Eco Rl site of pGEM 4 to make pUG5.0. pUG5.0 was then digested withEco 
Rl and partially digested with Bam ill, to release a 3.3-kb Eco Rl-Bam ill fragment. This 
fragment was purified from an agarose gel, treated with T4 DNA polymerase to generate blunt-
ends and blunt-end cloned into the Eco Rl site of pBluescript (DeMayo et al 1991b) to give 
pUG3.3. The HNE fragment obtained by digestion of pPB74 (Takahashi et al1988a) with Eco 
NI and purification from an agarose gel, was blunt-ended with Klenow DNA polymerase and 
cloned into the Eco RV site ofpUG3.3 (Figure 2.1). Ligation products ofpUG3.3 with HNE as 
well as of controls were run in an agarose gel prior to transformation to check for proper ligation 
(Figure 2.2). pUG3.3 and HNE successfully ligated, as demonstrated by the presence of several 
bands in lane 2. As for controls, Eco RV-digested pUG3.3 by itself ligated (Lane 3); blunt-
ended pPB74~ (see Chapter 3) ligated (Lane 4), whereas untreated pPB74~ did not ligate (Lane 
6) demonstrating successful end-filling; dephosphorylated Eco RV-digested pUG3.3 (Lane 5) 
did not ligate, demonstrating successful dephosphorylation. 
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Uteroglobin 
RI 3.3 Kb B 
pUG 3.3 
B 
N 
Eco RV Eco NI 
B B 
0.11 kb 
pUGHNE 
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Human Neutrophil Elastase 
RI E E RI 
pPB 74 
c 
Figure 2.1: Construction of pUGHNE for microinjection. RI: Eco RI; B: Bam HI; 
C: CIa I; N: Not I; E: Eco NI. The probe used for Southern blotting is 
represented by the arrow. 
Figure 2.2: 
6 .3 kb 
2.7 kb 
Agarose ge l electrophoresis of ligation products. 
Lane J: Ie Hind III molecular weight marker. 
Lane 2: Ligation product of Eco RV digested and dephosphorylated 
pUG3.3, and blunt-ended HNE fragment CEco NI digest of pPB74). 
Lane 3: Ligation product of Eco RV digested pUG3.3. 
Lane 4: Ligation product of blunt-ended pPB74L\. 
Lane 5: Ligation product of Eco RV digested and dephosphorylated 
pUG3.3. 
Lane 6: Ligation product of pPB74L\. 
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The ligation product shown in Figure 2.2 (Lane 2) was used to transform competent DH5a 
E. coli. Plasmid DNA was extracted from antibiotic-resistant colonies and analysed for 
integration by restriction digestion with Hinc II (Figure 2.3). Of six independent colonies 
analysed, two showed a 1.7-kb and a 9.3-kb band (Figure 2.3 b), compatible with insertion of 
HNE in the Bco RV site of pUG3.3 in the correct orientation. A map of the resulting plasmid is 
given in Figure 2.3 a. Lanes 3 and 4 correspond to insertion in the wrong orientation; Lane 6 is 
pUG3.3. The plasmid shown in Lane 5 could not be identified according to its restriction pattern 
and may have resulted from contamination. Clone 2 from Figure 2.3 was digested again with 
Hinc II and further checked by restriction digestion with Sac Land double digestion with Not 1-
CIa I (Figure 2.4). All digestions gave restriction fragment sizes compatible with the restriction 
map of pUGHNE (Figure 2.3 a). DNA from clone 2 was then digested with Not I and CIa I 
and an 8-kb fragment containing UG3.3, HNE, and 50 bp of vector sequence was purified from 
an agarose gel and used for microinjection into mouse embryos. 
Sac I 
( 10985) 
Not 1(1) Bam HI (20) 
Cia I 
(8050) 
Sac I 
(7500) 
Sac I 
(6800) 
Hinc II (6400) 
pUGHNE 
IIOOObp 
HNE 
Bam HI (2900) 
Figure 2.3 a : Map of pUGHNE. 
Figure 2.3 b: 
- 9.3 kb 
1.7 kb 
Restriction digestion analysis of miniprep DNA from the ligation 
product of pUG3 .3 and HNE. 
Lane I: Ie Hind III molecular weight marker. 
Lanes 2-7: miniprep DNA digested with Hinc II. 
Lanes 2 and 7: recombinant plasmid with insert in the right 
orientation as demonstrated by the presence of a 1.7-kb and a 9 .3-kb 
bands. 
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Figure 2.4: Agarose gel analysis of pUGHNE. 
Lane I: A. Hind III molecular weight marker. 
Lane 2: pUGHNE digested with Hinc II. Band 
sizes are 9.3 kb and 1.7 kb. 
Lane 3: pUGHNE digested with Sac I. Band 
sizes are 6.8 kb. 3.5 kb and 0.7 kb. 
Lane 4: pUGHNE digested with Not I and Cia 1. 
Band sizes are 8 kb and 3 kb . 
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2.2.2 Krev-l constructs 
2.2.2.1 pUGKREV 
To make pUGKREV, plasmid pKrev-l which consists of the human Krev-l cDNA cloned 
into expression vector pCD2 (Kitayama et al 1989), was digested with Hind III and Sal I 
resulting in the release of a DNA fragment containing human Krev-l cDNA (minus 
approximately 100 base pairs of 5' -untranslated region), the polyadenylation region of 
SV40 downstream from the cDNA, and 2.5 kb of vector sequence downstream from the 
polyadenylation region. The released DNA fragment was then cloned downstream from the 
uteroglobin promoter into the Hind III and Sal I sites of pUG 3.3 (Figure 2.5). 
Figure 2.6 shows the ligation product of pUG3.3 with Krev-l. Ligation of sticky-end 
fragments was very efficient with mainly high-molecular weight DNA obtained. The 
ligation product shown in Figure 2.6 Lane 2 was used to transform DH5a E. coli and 
plasmid DNA was extracted from ampicillin-resistant colonies and digested with BamH I. 
Recombinant plasmids were identified by the presence of 3 bands of 5.9 kb, 2.9 kb and 2.2 
kb after digestion with Bam HI. As shown in Figure 2. 7b, from 14 colonies, 3 were 
recombinant (lanes 5, 7 and 14). All 3 recombinant plasmids were in the right orientation 
since directional cloning was used. The other clones shown in Figure 2.7 are compatible 
with the restriction patterns of pUG3.3 (lanes 1, 3 and 10), or of self-religated Krev-1 (lanes 
6, 8, 9,11, and 13). Plasmids in lanes 2 and 4 were not identifiable by their restriction 
pattern and may be contaminating plasmids. The identity of pUGKREV was further 
checked by restriction digestion with Acc I and Sac 1. The expected 5.4-kb, 3.5-kb, and 
2.1-kb restriction fragments were obtained (Figure 2.8). The 5.4-kb Acc I-Sac I UGKREV 
fragment was used for microinjection of mouse embryos. 
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Uteroglobin 
Eco RI 3.3 Kb Bam HI 
.1 ------~_~-----.~I_ 
pUG 3.3 
Sail 
Bgi II 
Sac I 
Hind III 
Sail 
Hind III 
Hind III 
Sail 
pUGKREV 
Hind III 
Acc I 
Krev-1 
eDNA 
pKREV-1 
Sail 
Acc I 
Figure 2.5: Construction of pUGKREV for rnicroinjection. The probe used in 
Southern blotting is shown by the arrow. E~i SV 40 polyA region. 
am Krev-l 5' untranslated region. 
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Figure 2.6: 
1 23M 
Agarose gel electrophoresis of the product of pUG3.3 and Krev- l 
ligation. 
Lane M: A Hind III molecular weight marker. 
Lane I: pUG3.3 digested with Sal I and Hind III and religated. 
Lane 2: product of ligation of Krev-J and pUG3.3. 
Lane 3: pUG3.3 digested with Eco RV, dephosphorylated and ligated. 
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Figure 2.7a: 
SIiC I 
( 11 000) 
l1urn HI ( J) 
pUG KR EV 
1I000bp B am 11 1(2900) 
Hind JII(3300) 
Krev- l 
Ace I Bllm ll l(5 100) 
(5400) 
Map of pUGKREV 
Resticti on site pos itions are approximati ve (the 5' untranslated region of 
Krev- I has not been completely ~equenced). 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 M 
5.9 kb 
2.9 kb 
- 2.2 kb 
Figure 2.7 b: Restriction digest analys is of miniprep DNA from the ligation product of 
pUG3.3 with Krev- 1. 
Lane M: Ie Hind III molecular weight marker. 
Lanes 1-14: mini prep DNA digested with Bam HI 
Lanes 5, 7, and 14 have a restriction pattern compatible with pOGKREV. 
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1 M 
5.4 kb 
3.6 kb 
2.1 kb 
Figure 2.8: Agarose gel analys is of pUGKREV DNA digested with Acc I and Sac 1. 
Miniprep DNA from clone 5 (Figure 2.7 b) was used. The banding pattern 
is compatible with that of pUGKREV. 
Lane M: t.. Hind III molecular weight marker 
Lane I : miniprep DNA digested with Sac I and Acc I 
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2.2.2.2 pUKH 
To make pUKH, a mutated human Krev-1 cDNA, in which Gln63 was replaced by Glu, was 
excised by Hind IIIIBsm I digestion from pKrev63G (Kitayama et al 1990) as a 1-kb 
fragment containing the complete coding sequence, translation start codon and stop codon, 
but lacking a polyadenylation signal, and cloned into the Hind III and Sal I sites of pUG3.3 
to give pUGKrev-1 (Glu63). Blunt-end cloning into the Apa I site downstream of the cDNA 
in pUGKrev-1 (Glu63) was then used to insert a 4.5-kb HNE genomic fragment providing 
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the complete HNE coding sequence minus the first 23 bp and a polyadenylation signal but 
lacking a translation start site, which had been excised from pPB74 (Takahashi et al1988) 
with Drd I and Eco RI (Figure 2.9). 
To make pUGKREV-1(Glu63), double-digested pUG3.3 and Krev-1(Glu63) were incubated 
in the presence of DNA ligase for 30 min to ligate the compatible termini generated by Hind 
III. Figure 2.10 shows an agarose gel electrophoresis of the ligation product. Several 
bands are visible in the gel, demonstrating successful ligation. The most abundant band is a 
7.3-kb band corresponding to a single insert-vector ligation. Other bands correspond to 
insert-insert ligations and to concatemers of more than 2 molecules as well as to circular and 
supercoiled plasmids. No bands corresponding to unligated fragments are visible. 
Stop 
ATG I AATAAA 
----1 J KreVf)~GJ}-
ATG 
Hind III 
--t1 
- - --- -_ .. __ ._- -------.-- -----"" 
.. I 
Not I 
UG 3.3 
Sail 
Kpn I 
Apal 
pUKH 
Figure 2.9: Construction of pUKH for microinjection 
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HNE AATAAA 
1 M 
Figure 2.10: Agarose gel electrophoresis of the 
product of pUG3.3 and Krev- I (Glu63 )ligation . 
Lane M: A Hind ill molecular weight marker. 
Lane I: ligation product. 
The arrow points to a 7.2-kb band corresponding to 
vector-insert ligation. 
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The ligation product was then treated with T4 DNA polymerase to blunt-end the 
incompatible termini generated by Sal I and Bsm 1. The DNA was diluted and rcincubated 
in the presence of li gase, then used to transform DHSa E.coli. Miniprep DNA extracted 
from ampicillin-resistant colonies was restriction-digested with Pst I and run in an agarose 
gel (Figure 2. 11 b). Eight out of 12 antibiotic-resistant colonies showed a l.3-kb band 
corresponding to 600 bp of Krev- I sequence and 700 bp of UG sequence (Figure 2.1 I a) 
prov ing that they were recombinant and the inselt was in the correct orientation. The 4 
other bands (3 .3 kb, I kb, 0.8 kb , and 0.6 kb) co rrespond to Pst I-fragments of pBluescript 
or UG3.3 (Figure 2. 11 a). According to the banding pattern shown on the gel (Figure 2. 1 I 
b), the other 4 colonies were pUG3 .3. 
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The new plasmid (pUGKREV -1 (Glu63)) was digested with Apa I and blunt-end ligated to a 
human neutrophil elastase (HNE) DNA fragment obtained by digesting pPB74 with Drd I 
and Eco RI, using the 2-step ligation method as described in Chapter 3, to yield pUKH 
(Figure 2.12 a). Figure 2.12 b shows anagarose gel of Bam HI-digested rniniprep DNA 
extracted from ampicillin-resistant colonies obtained after transformation of DH5a cells 
with the ligation product. As deduced from the map in Figure 2.12 a, restriction digestion 
with Bam HI gives 4 bands of 4.5 kb, 2.9 kb, 2.6 kb, and l.8 kb, in case of integration of 
HNE in the right orientation and 4 bands of 3.3 kb, 3.0 kb, 2.9 kb, and 2.6 kb in case of 
integration of HNE in the wrong orientation. Three recombinants out of 14 clones were 
identified~ Two had the HNE-fragment in the wrong -orientation (numbers 7 and 10) and 
one in the correct orientation (number 11), as demonstrated by their restriction digestion 
patterns. Clone 8 was not identifiable from its restriction pattern and corresponded 
probably to contaminating DNA. All other clones have a restriction pattern compatible with 
pUGKREV-1(Glu63). Clone 11 was further checked by restriction digestion with Not I 
and Kpn I (Figure 2.13) which release the UKH fragment from the vector. The expected 9-
kb and 2.8-kb bands corresponding to UKH and to pBluescript, respectively, were 
obtained. The 9-kb UKH fragment obtained by restriction digestion with Not I and Kpn I 
was used to produce transgenic mice. 
Kpnl (4950) 
pUGKREV-l (G lu63) 
7200bp 
PSII (1300) 
uo 
Allai (4 ) 
Krev-~ 
PSII (4600) 
Hindlll (4000) 
PSII (3300) 
Figure 2.11 a: Map of pUGKREV-I (Glu63). 
Restriction site positions are approximate because the 5' untranslated 
region of Krev-I (Glu63) has not been fully sequenced. 
2 3 4 5 6 7 B 9 10 11 12 13 
Figure 2.11 b: Restriction digestion analysis of miniprep DNA from the ligation product 
of pUG3.3 and Krev- I (Glu6'). 
Lane I: A. Hind III molecular weight marker. 
Lanes 2-13: miniprep DNA digested with Pst I. 
Lanes 2-8 and 13 show 5 bands of 3.3 kb, 1.3 kb, I kb, 0.8 kb, and 0.6 
kb compatible with the restriction pattern of pUGKREV- J(Glu63 ) 
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Kpn I (9600) 
HNE 
Figure 2.12 a: Map of pUKH. 
pUKH 
11 800bp 
Dllm HI (5400) 
UG 
8ml1 HI (J600) 
Krev- l 
Figure 2.12 b: Restriction digestion analysis of miniprep DNA from thc ligation product 
ofpUGKREV- I(Glu63) and HNE. 
Lane M: Ie Hind III molecular weight marker. 
Lanes 1- 14: miniprep DNA digested with BamH I. 
Lane II : recombinant plasmid with HNE in correCl ori entati on as 
demonstrated by the presence of 4 .5-,2.9-,2.6-, and 1.8-kb bands. 
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1 M 
9 kb -
2.8 kb_ 
Figure 2.13: Agarose gel analysis of pUKH 
DNA digested with Not I and Kpn I. 
Lane M: A Hind III molecular weight marker. 
Lane 1: pUKH digested with Not I and Kpn 1. 
DNA from clone II (Figure 2. 12b) was used . 
Bands of 9 kb and 2.8 kb are present and are 
compatible with the banding pattern of pUKH. 
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2.3 Production of transgenic mice 
The detailed protocol used to produce transgenic mice is described in Appendix 1. Here 
the principles of the procedure are described briefly. 
Swiss Random White (SRW) mice were used as donors and recipients with the 3 
microinjected constructs. With UGKREV, NJ mice were also used as donors. 
Immature female mice were superovulated by intraperitoneal injection of pregnant mare 
serum gonadotropins (PMSG) which induces recruitment and maturation of ovarian 
follicles, followed by injection of human chorionic -gonadotropins (hCG) whose LH-like 
effect induces ovulation. Fertilisation was obtained by mating the superovulated females 
with an intact SRW male. Twenty-four hours after the HCG injection, the mice were 
sacrificed and the eggs collected by flushing the oviduct. At the time of flushing, the 
zygotes are 12 hours of age, are at the one-cell stage, and have two visible pronuclei. The 
DNA to be injected was excised from the appropriate plasmid by restriction digestion and 
purified from an agarose gel using glass milk. After purification the DNA was 
microinjected into the pronucleus of one-cell embryos using a pulled glass micropipette. 
Microinjection was carried out under 400X magnification using interference contrast 
mlcroscopy. Recipient females were given an injection of PMSG and mated with a 
vasectomised male on the same day as donors. Females who mate with the vasectomised 
males become pseudopregnant and are suitable recipients. Microinjected zygotes that did 
not lyse after the microinjection were implanted into pseUdopregnant recipients and allowed 
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to develop to term. Three weeks after birth, at weaning, DNA was extracted from a tail 
biopsy (Appendix 2) and analysed for trans gene integration (Hogan et aI1986). 
Animals were housed in cages at 22 ± 3°e under lights from 5 am to 7 pm and given food 
and water ad libitum. 
2.4 Screening of transgenic mice 
DNA isolated from tail biopsies of mice after weaning was digested with restriction 
endonucleases. Bam HI was used for UGHNE mice and BgllI for UGKREV and UKH mice. 
Digested mouse DNA was electrophoresed through a 0.8% agarose gel in TBE and transferred 
to GeneScreen Plus nylon membrane. The DNA was transferred to the membrane according to 
the capillary transfer method (Sambrook et al 1989) in the presence of alkaline buffer (OAN 
NaOH, 0.6M NaCl). After transfer, the membrane was neutralised by washing twice for 15 mins 
in 0.5 M Tris pH 7A, 2X sse (IX sse is 0.15M sodium chloride and 0.015M sodium citrate) 
then prehybridised in 1 % (w/v) sodiumdodecyl sulfate (SDS), 10% (w/v) dextran sulfate and 
1 M sodium chloride for at least 15 min. TheentireUG3.3 was labelled with 32p_dCTP by 
random priming using an Amersham kit, as recommended by the manufacturer, purified through 
a Sephadex G50 column, and used as a probe. The radioactive probe was mixed with 500 III 
herring sperm DNA (1 mglrnl) , denatured by boiling for 10 mins and added to the bag containing 
the membrane and the pre-hybridisation solution. Hybridisation was allowed to proceed 
overnight at 650e in a bag placed in a water bath or in a hybridisation bottle using a Hybaid 
hybridisation oven (Hybaid, Teddington,UK). After hybridisation the membrane was washed 
twice in 2X sse at room temperature for 5 mins, twice in 2X ssell % SDS at 650e for 30 
53 
mins, and twice in O.IX SSC for 30 mins at room temperature. The membrane was then 
wrapped in Glad-Wrap to prevent drying and exposed to XAR X-ray fIlm for 1 to 7 days. 
Founder transgenic mice (GO) were bred to wild-type mice to produce transgenic lines. In the 
case ofUGHNE, GOs were crossed with SRW mice .. Jnthe case ofUGKREV and UKH, GOs 
were crossed with AI] mice to introduce the transgene into AI] background. Offspring were 
screened for transgene integration either by Southern blotting or by PCR ampliflcation of an 879 
bp region of UG sequence (Appendix 3) usmg primers UG 1 
5'(GAGCCAATGACTGAAGCTCA)3' andUG2 S(ATGG'fGACCT AGCCACCTGC)3' 
that do not amplify wild-type mouse DNA. 
2.5 Northern blotting 
Mice were sacrificed by cervical dislocation and total RNA was extracted from lung, liver, 
spleen, kidney, gut, skin, brain, heart, testes or ovaries, uterus or seminal vesicles, pancreas, 
and thymus according to the method of Chomczynski and Sacchi (1987). 
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Twenty ~g RNA were denatured by heating at 65°C for 15 min in RNA denaturing buffer (20 
ruM Hepes, 5 ruM sodium acetate, 1 ruM EDTA, 60% formamide, and 8% formaldehyde) and 
electrophoresed through a 1.5% agarose gel containing 6.6% (v/v) formaldehyde in phosphate 
buffer (10 ruM NaH2P04, 10 ruM Na2HP04, pH 7). After electrophoresis the RNA was 
transferred to GeneScreen Plus membrane as described (Sambrook et al 1989) and hybridised 
with a probe labelled with 32p_dCTP by random priming. For UGHNE mice, a HNE cDNA 
extracted from pPB 15 (Takahashi et al 1988a) was used. For UGKREV mice, a Krev-l cDNA 
was used. For UKH mice both Krev-l and HNE cDNAs were used in separate blots. The 
hybridisation and washes were carried out as for Southern blotting. Total RNA from cell line 
U937 expressing a high level of HNE was used as positive control for UGHNE and UKH 
Northerns. 
2.6 Ribonuclease protection assay 
Ribonuclease protection assay (RPA) was performed using an Ambion kit according to the 
manufacturer's recommendations. Hybridisation was at 45°C overnight. RNase digestion 
was with 0.05 U RNase A and 2 units RNase Tl in 220"f.l1 at 37QC for 30 min. To make the 
riboprobe, a DNA fragment containing 0.7 kb of UG promoter sequence and 0.6 kb of 
Krev-l cDNA 5' sequence was excised from pUGKREV by restriction digestion with Pst I 
and cloned into the Pst I site of pBluescript to make pUK (Figure 2.14). pUK was then 
linearised by digestion with Ssp I and an antisense riboprobe was transcribed with T3 RNA 
polymerase in the presence of 32p UTP (800 Cilmmol) using a Boehringer riboprobe kit, 
according to the manufacturer's instructions. For a positive control, the entire Krev-l 
cDNA was excised from pKrev-l (Kitayama et al 1989) with Hind_III and Sal I and 
subcloned into the Hind III-Sal I sites of pBluescript to yield pKrev-2. pKrev-2 was 
linearised with Hpa I and used as a template to produce a sense Krev-l RNA which was 
mixed with non..,transgenic mouse lung RNA and used as a positive control in the RPA. To 
monitor RNA concentration, a mouse actin probe (provided with the RP A kit) was mixed 
with the Krev-l probe. 
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Figure 2.14: Construction of pUK and synthesis of riboprobe by RP A 
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2.7 Purification of HNE from Bronchoalveolar Lavage Fluid of Transgenic Mice 
Bronchoalveolar lavage (BAL) fluid was obtained from UGHNE transgenic mice by direct 
cannulation of the trachea under anaesthesia with sodium pentobarbital. Five l-rnl portions of 
warm saline were washed sequentially through the lungs, with approximately 4.5 rnl recovered. 
Cells in BAL were removed by centrifugation for 10 min at 2500 x g. 
BAL of 6 mice were concentrated in Centric on 30 cells and desalted with a PD 10 column 
(Sephadex G-25M) in low-salt buffer (50 mM potassium phosphate, 0.075% Tween 20, pH 
7.4). Complexedand free HNE were then purified; essentially as described by Opas et al. 
(1991), on a CM-cellulose (Whatman CM23) column. Complexed HNE was eluted in the low-
salt wash and free HNE eluted with high-salt buffer (1M NaCI, 50 mM potassium phosphate, 
0.075% Tween 20, pH 7.4). 
2.8 Western and Dot Blot Analysis of Purification Fractions 
Fractions from the CM23 column were spotted onto nitrocellulose and allowed to air dry. For 
Western blotting, fractions were concentrated in Centric on 30 cells and analysed by 10% 
non-reducing PAGE. Proteins were then transferred to nitrocellulose and the fIlters were 
blocked for at least 30 min in PBST (137 mM NaCl, 2.7 mM KCI, 4.3 mM Na2HP04, 1.4 mM 
KH2P04,0.05% (v/v) Tween-20) containing 3% (w/v) dried non-fat milk. HNE was detected 
by incubation with a biotinylated anti-HNE mouse monoclonal antibody, overnight at room 
temperature. Filters were washed thoroughly with PBST then incubated with 
streptavidin-biotin~horse radish peroxidase (HRP)conjugate for 1 h. Filters were washed again, 
then developed by incubation in 10 ml methanol containing 30 mg 4-chloro-naphthol. 
2.9 Quantitation of HNE in mouse BAL 
HNE levels were quantitated by -a double~antibodyenzyme-linked-immunosorbant assay 
(ELISA). The protocol was essentially as described by Ochnio et al. (1991), except that 
antibody dilutions were optimised for the antibodies we obtained and detection was by HRP. 
2.10 HNE Activity Assay 
HNE activity was measured using the synthetic substrate N-methoxy-succinyl-Ala-Ala-Pro-Val 
p-Nitroanilide. Buffer (50 mM Tris, 200 mM NaCl, pH 7:5)-and samples (including standards) 
were added to a micro titre plate (NUNC) in a [mal volume of 190 III per well. After 
equilibration at 37°C, 10 III of substrate (10 mg/ml) was added, and the plate reincubated at 
37°C. Absorbance at 405 nm was read at various intervals. 
2.11 Immunohistochemistry and morphology 
UGHNE transgenic animals were given a lethal dose of sodium pentobarbital. After death, lungs 
were perfused with buffered formalin (1% (v/v) formaldehyde in 0.2 M phosphate buffer), 
. through a tracheal cannula for 24 h at 20 .em H20 pressure. Fixed lungs were then removed, 
dehydrated with alcohol, cleared with xylene and embedded under vacuum in paraffin. Four-
micron sections were cut and stained with haematoxylin-eosin. For immunohistochemistry 4-
micron sections were cut and incubated with rabbit anti-HNE antiserum overnight at 4°C, as 
described by Hsu and Raine (1981). Detection of streptavidin-HRP was with diaminobenzidine 
solution. 
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2.12 Tumourigenesis 
Transgenic mouse lines with a predominantly AlJ background were derived by crossing 
SRW transgenic males with AlJ females, and crossing transgenic G 1 males with AlJ females 
to produce G2 offspringof75%AlJ-genotype. One pure line (1803) was derived by mating 
an AlJ transgenic male with AlJ females. 
Transgenic descendants of UGKREV and UKH founder mice and non-transgenic littermates 
were given ethyl carbamate (1 mg/g body weight)-as a singlei.p. injection at 6 weeks of 
age. Males and females in each litter were caged separately. Sixteen weeks after the 
injection, the mice were sacrificed by cervical dislocation and their lungs were removed. 
The lobes were separated, placed in a Petri dish containing phosphate-buffered saline (137 
mM NaCl, 2.7 mM KCI, 4.3 mM Na2HP04, 1.4 mM KH2P04, pH 7.4), and examined under a 
dissecting microscope at lOx magnification. The tumours were counted immediately after 
dissection, without prior knowledge of the transgenic status of the mouse. 
2.13 Histology 
Transgenic and wild-type mice were given ethyl carbamate as described above. Sixteen 
weeks after the injection, the mice were sacrificed and their lungs removed and examined 
under a dissecting microscope. All visible tumours were dissected individually, along with 
some of the surrounding normal tissue. Tumours from each mouse were embedded in one 
paraffin block, sectioned, stained with haematoxylin and eosin, and examined by light 
microscopy. Tumour types were assigned according to the classification of Kauffman and 
Sass (1979) in a blind study by an independent pathologist. 
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2.14 ras mutations 
Three mice (2 transgenic and one control littermate) were given ethyl-carbamate as 
described above. Eighteen months after the carcinogen injection, mice were sacrificed by 
-cervical dislocation and the lungs removed. All visible tumours were carefully dissected 
under a stereomicroscope with special attention paid to avoiding contamination with 
normal lung tissue. Non-tumour lung tissue was also taken from the 3 mice. 
DNA was extracted from -tumour-and- normal lung tissues by incubation in a solution 
containing 0.15 M NaCl, 20 mM Tris-HCI pH 7.8,1 mM EDTA, 1 % SDS, and 0.5 mg/ml 
pronase at 37°C overnight, followed by phenol-chloroform extraction and 2 ethanol 
precipitations. 
Sequences surrounding K-ras codon 12 and codon 61 were amplified by PCR using 
primers CTGAAAA TGACTGAGTAT AAACTTG and 
CTCTATCGT AGGGTCGTACTCATCC for codon 12, and primers 
GGACTCCTACAGGAAACAAGTAGTA and CCTATAATGGTGAATATCTTCAAAT 
for codon 61. The PCR conditions were 35 cycles of 94°C for 10 seconds, 59°C for 1 
minute, and 72°C for one minute, followed by one cycle of 7 minutes at 72°C. The PCR 
reaction mixture contained 50 ng template DNA, 250 nM each primer, 200 ~M dNTPs, 10 
mM Tris-HCI pH 8.3, 2.5 mM MgCh, 50 mM KCI, and 1.5 units Taq DNA polymerase, in 
a volume of 50 ~l. 
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PrimersAAGTGATICTGAATTAGCTG and AATTGATGGAGAAACCTGTC were 
used to sequence the codon 12 and 61 regions, respectively. Primers were end-labelled 
with 32p using polynucleotide kinase and 32p yATP as described (Ausubel et aI1987). 
PCR-amplified tumour DNA (0.5 ng) was sequenced without further purification 
according to the cycle sequencing procedure using theftnolDNA sequencing system, 
according to the manufacturer's instructions. 
2.15 Statistical analysis 
The tumour data were analysed using the general linear model of Minitab (Mini tab reference 
manual, 1993) run on a personal computer. To determine the effect of Krev-1 on tumour 
multiplicity in each of the 3 lines, the data from each line were analysed separately. The 
effect of transgenic status on the number of tumours per mouse was analysed with 
consideration given to the variation due to sex and litter. The model was: tumour 
number/mouse=transgenic-status sex litter. The interactions between factors were not 
significant, except for Line 2610 where the interaction between transgenic status and sex 
was significant, and were removed from the model. The data from the 3 lines were also 
pooled and analysed together using the same model to determine the overall significance of 
the transgenic status, regardless of the transgenic mouse line. The results are detailed in 
Appendix 4 with a summary of the results in Table 6.1. 
Results from the histology of tumours were analysed by Chi-square. 
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Chapter 3 
Improved methods for blunt-end cloning 
3.1 Introduction 
In the course of producing the plasmids used in this work,blunt-end ligation was required. 
The blunt ends were generated by end-filling of overhangs resulting from restriction 
digestion. Since this method is inefficient, an improvement of the method for blunt-end 
ligation (Damak and Bullock 1993) and a positive control for end-filling prior to blunt-end 
ligation were developed. 
3.1.1 Blunt-end ligation 
Blunt-end ligation is widely used to join DNA molecules with incompatible ends and to 
clone polymerase chain reaction products. Ligation occurs when a phosphodiester bond is 
formed between the phosphate group at the 5' end of a DNA molecule and the hydroxyl 
group at the 3' end of another DNA molecule. The reaction is catalysed by DNA ligase, the 
most commonly used in the laboratory being T4 DNA ligase. When the 2 DNA molecules 
to be ligated have protruding single-stranded compatible ends (generally produced by 
restriction endonucleases), base paring of the protruding ends bring the ends of the 2 
molecules together and ligation is strait-forward. However, when the ends of the DNA 
molecules are blunt, the ligation reaction is less efficient. Because T4 DNA ligase is 10 to 
100 times less efficient with blunt-end ligation than with sticky-end ligation (Ausubel et al 
1987), obtaining recombinant plasmids at high efficiency is often difficult. 
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-Low. lig.ation efficiency also makes it difficult to identify recombinant clones among 
background clones resulting from uncut vector or self-ligating vector. Several approaches 
have been proposed to overcome this problem. Dephosphorylation of the 5' end of the 
vector dramatically decreased the incidence of self-ligation (Ullrich et al 1977). Addition of 
a restriction endonuclease to the ligation mixture was· shown to reduce background by 
cutting self-ligated vector and undigested vector (Liu and Schwartz 1992). This approach 
is not always possible, however, because of incompatibility between the ligase buffer and the 
restriction enzyme buffer or the presence in the insert of the recognition site for the 
restriction endonuclease. The blue/white colour selection method, where an E. coli ~­
galactosidase gene (LacZ) present in the vector is disrupted by the insert during the cloning 
process (Ausubel et al 1987), permits discrimination between recombinant and background 
colonies on the basis of colour. This method is possible only with vectors harbouring an 
intact LacZ gene; it is not applicable with many vectors that do not contain a LacZ gene or 
with blue/white vectors in which an insert has already been cloned. 
The construction of a recombinant. plasmid is a two-step process in which DNA 
concentration plays a key role. The first step is an intermolecular event in which one end of 
the vector ligates with one end of the insert. This event is favoured by high DNA 
concentrations at which a given molecule is more likely to ligate with the end of another 
molecule than to self-ligate (Dugaiczyk et at 1975). The second step is self-ligation of the 
newly formed hybrid molecule (intramolecular ligation). This step is favoured by low DNA 
concentrations at which one end of the molecule is more likely to ligate with the other end 
of the same molecule. 
The size-of the DNA molecule is also important. At a given DNA concentration, longer 
fragments are more likely to form concatemers and smaller fragments to self-ligate. The 
relationship between DNA concentration and molecular weight (MW) is given by the 
equation MW = (51.1I(j/i[DNADi, where j is the concentration of one DNA terminus in the 
neighbourhood of the other on the same molecule,-i is the local concentration· of all termini, 
and [DNA] is the total DNA concentration (Dugaiczyk et al 1975). At high jli ratios (>3), 
self-ligation tends to occur, whereas at low jli ratios «1) intermolecular ligation is favoured 
(Dugaiczyk et al 1975). To allow both ligation events to occur and result in a recombinant 
plasmid, a compromise j/i ratio >1 and <3 is usually recommended (Sambrook et aI1989). 
3.1.2 End-filling 
To join DNA fragments with incompatible 5' overhanging ends, the ends of the molecules 
are routinely blunt-ended using the Klenow fragment of DNA polymerase I before blunt-end 
ligation. Ligation of blunt-ended DNA fragments often results in poor transformation 
efficiency and a positive control which demonstrates that the end-filling reaction had 
succeeded would be a useful diagnostic tool. A DNA fragment with two 5' overhangs that 
can neither self-ligate nor ligate with another molecule of the same DNA species can be 
used as such a positive control; blunt-end cloning would then be successful only if the ends 
had.been correctly filled in. Most common restriction enzymes such as Eco RI, Bam HI, 
Hind III generate symmetrical overhangs. Because they are symmetrical these single-
stranded overhangs can hybridise with another overhang produced by the same enzyme and 
therefore are not useful as a positive control for end-filling prior to blunt-end ligation. 
Other common restriction enzymes such as Eco RV or Sma I, generate blunt ends, which 
can religate without further processing. 
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To be used as positive control for end-filling, a DNA molecule must have ends that cannot 
self ligate, ie. neither be blunt nor have ends compatible with each other. Although not 
commonly used in molecular biology, several restriction enzymes that generate asymmetrical 
ends are -available. These enzymes recognise a symmetrical sequence but cut the DNA 
molecule at a given distance from the recognition site. The cut site is therefore totally 
random and in most cases asymmetrical. A search in the RE database of the GCG 
computer programme (Genetics Computer Group 1991) found that restriction enzymes that 
generate incompatible 5'-ends number 110 and include Alw I,Bsa I, Bsm AI, Bsp MIand 
Eco NI. The enzyme Eco NI, for example, has the recognition sequence CCTNNIN-
NNAGG, where / and- indicate the cut site in the plus strand and minus strand, 
respectively. 
3.2 Positive control for end filling prior to blunt-end ligation 
3.2.1 Experimental design 
In order to produce a plasmid that can neither self-ligate nor produce concatemers unless 
end-filled prior to ligation, pPB74 was digested with Eco NI and a 2.7-kb fragment 
containing essentially pUC 19 sequence (pPB74~) with a protruding G at each end was 
generated (Figure 3.1). 
pPB74~ was extracted from an agarose gel and purified with GeneClean. To test pPB74~ 
as a positive control for end-filling, end-filled and untreated pPB74~ were compared by 
ligating 200 ng DNA each and running the digestion product in a 0.8% agarose gel. 
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Figure 3.1: Construction of pPB74~ and its use as positive control for end-ftlling 
reactions. 
o:IJ] human neutrophil elastase genomic DNA;'. _.' pUC19; 
E, Eco NI. 
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3.2.2 Results and Discussion 
Agarose gel electrophoresis of end-filled and ligated pPB74Ll showed several bands 
corresponding to 1, 2, and 3 copies of the plasmid as well as supercoiled and circular forms 
(Figure 3.2, lane 2), whereas pPB74Ll that was not repaired to create blunt ends did not 
ligate, as demonstrated by the presence of a single 2.7-kb band (Figure 3.2, lane 1). This 
proved that the end-filling reaction was successful. The experiment was repeated twice, 
. with similar results. 
Unlike ends generated by restriction endonucleases that have symmetrical recognition 
sequences, the ends generated by Eco NI (in this case 5' overhanging G), are not compatible 
and cannot ligate with each other unless the DNA fragments have been end-filled. This 
strategy is applicable to all such enzymes. When the fill-in reaction requires all 4 
nucleotides, an enzyme that generates a 5'-overhang with the 4 nucleotides may be used to 
produce the positive control plasmid. This method provides a simple positive control to test 
reagents and experimental conditions of the end-filling reaction to ensure that repair of 
DNA ends has gone to completion; it offers a useful tool in diagnosing the frequent low 
efficiency of blunt-end cloning. 
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• 2.7 Kb 
Figure 3.2: Analysis of ligation products on a 0.8% agarose gel M: /.. Hind III 
molecular weight markers. I: unprocessed and ligated pPB74L'.. 2: end-
fJ.!led and ligated pPB74L'.. The electrophoresis buffer was 0.09M TJis, 
0.09M boric acid , 0.002 M EDTA (TBE) containing 0.5 flglml ethid ium 
bromide. 
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3.3 A simple two-step method for efficient blunt-end ligation of DNA fragments 
To improve the efficiency of blunt-end ligation, a 2-step method was developed in which 
the DNA concentration is initially made optimal for intermolecular ligation then made 
optimal for intra-molecular ligation. 
3.3.1 Experimental design 
As a test of the method, full-length cDNA of the tumour suppressor gene Krev-l (Kitayama 
et a11989) was blunt-end cloned into the EcoRV site of pBluescript. Krev-l cDNA was 
excised from pKrev-l (Kitayama et al 1989) by digestion with Bam HI and purified as a 
1.9-kb fragment by electrophoresis inagarose onto DEAE-paper. The insert was end-filled 
by incubation with the Klenow fragment of DNA polymerase 1. pBluescript was digested 
with Eco RV and tested by electrophoresis for completeness of digestion before being 
dephosphorylated using calf intestinal alkaline phosphatase. 
The first step of the two-step ligation was carried out at a DNA concentration of 60 ng//ll 
vector and 60 ng//ll insert (iIi ratio = 0.32) for 1 hour. The reaction was then diluted 20 
times to give a j/i ratio = 6.3. T4 DNA ligase and buffer were adjusted to their original 
concentrations, and ligation continued overnight. 
Control one-step ligations were carried out overnight at total DNA concentrations of 120 
ng//ll (iii = 0.32), 19 ng//ll (iIi = 2) and 6 ng//ll (iIi = 6.3), with a mass ratio of insert to 
vector of 1.0. 
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.. 3.3.2 Results and Discussion 
Efficiency of the ligation was assessed by the number of antibiotic-resistant colonies 
obtained after transformation of E .coli with the ligation product. The numbers of colonies 
are shown in Figure 3.3. A similar number of background blue colonies was obtained with 
all transformations, including transformationwithunligated digested vector,whichsuggests 
that they resulted from residual undigested vector not detected by gel electrophoresis. The 
number of white recombinant colonies was almost 1O-fold higher in the two-step ligation 
than in the control ligation with the generally recommended j/i ratio > 1 and < 3 (4.1 x 104 
versus 3.3 x 103 transformations per /lg of DNA). Single-step ligations with j/i of 0.32 and 
6.3 gave an even lower recombinant yield (9.5 x 102 transformants//lg of DNA). Thus the 
high yield of recombinant clones obtained with the two-step ligation cannot be accounted 
for by either of the two ligations taken alone, but results from the combination of both 
conditions. 
To confirm that white colonies from the two-step ligation were recombinant and to test for 
size of insert, DNA was extracted from overnight cultures of 10 randomly picked colonies 
and digested with Eco RI, which cuts pBluescript once and does not cut the insert. Figure 
3.4 shows that the plasmids extracted from the 10 colonies w·ere recombinant and that each 
plasmid incorporated a single copy of the insert, based on the expected size of 4.8 kb (1.9-
kb insert plus 2.9-kb vector). Because the first step of the two-step ligation strongly 
favours the formation of concatemers, recombinant plasmids containing more than one copy 
of the insert were possible. Figure 3.4 indicates that such multiple-insert recombinants are 
rare, if present at all, in the recombinant plasmid population, perhaps because blunt-end 
ligation is inefficient. 
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Figure 3.3: Yield of recombinant clones under various ligation conditions. Bars 
show mean of duplicates ± pooled standard errors [degrees of freedom 
(dt) 6]. 
1. Two-step ligation 
2. Single-step ligation (iIi = 2) 
3. Single-step ligation (iIi = 0.32) 
4. Single-step ligation (iIi = 6.3) 
5. Self-ligated de phosphorylated vector 
6. Unligated dephosphorylated vector 
W White colonies (recombinant) 
B Blue colonies (background) 
BS 1 2 3 4 5 6 7 8 9 10M 
4.8 Kb .. 
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Figure 3.4: Agarose gel analysis of plasmid DNA extracted from E. coli transformed 
with the two·step ligation product and digested with Eco RI. 
BS: Bluescript 
M: A Hind III molecular weight marker 
1·10: Miniprep DNA from 10 randomly picked white colonies 
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Figure 3.5 shows an analysis of the ligation products after the first step. After a I-hour 
incubation at high DNA concentration, about 5 to 10% of the total DNA had ligated. The 
bands in Lane 2 correspond to the insert (1.9 kb), vector (2.9 kb), and duplex molecules of 
insert-insert (3.8 kb) and vector-insert (4.8 kb), resulting from single ligation events. As the 
probability of one molecule· undergoing two ligation events is very low, no bands 
corresponding to such molecules are visible. Moreover, such plasmids would be larger and 
therefore less likely to self-ligate when DNA concentration is lowered in the second step. In 
addition, they transform competent cells less efficiently than smaller plasmids (Hanahan 
1983). 
The duration of the first ligation was determined empirically. Preliminary experiments 
comparing 1 and 3 hours did not show a significant difference in the yield of recombinants. 
In our experience, some enzymes generate blunt ends that are harder to religate than others, 
e.g. Sma I compared to Eco RV. These more difficult ligations may require a longer first 
step incubation time. In such cases, the first ligation can be monitored by running aliquots 
of the reaction in an agarose gel at intervals. Once a sufficient amount of plasmid-insert 
recombinant molecules is produced, the second ligation can proceed. 
In summary, two-step ligation of blunt-end DNA fragments, using conditions first that 
favour intermolecular and second intramolecular ligation, is a simple method that 
dramatically increases the yield of recombinant plasmids. 
Figure 3.5: 
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Agarose gel analysis of the ligation reaction at the end of the first step of 
the two-step ligation. 
I . A Hind III molecular we ight marker 
2. Ligati on product 
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4.1 Introduction 
Chapter 4 
Production of transgenic mice 
Results 
Transgenic mice are useful models of human diseases which can be used to understand the 
physiology of diseases and to test the effectiveness and safety of potential therapies. Here we 
describe the generation of transgenic mice expressing either the human neutrophil elastase gene 
or the human Krev-l gene in their lungs under the control of the rabbit utero globin promoter. 
Transgenic mice with the elastase gene were generated in order to produce an animal model for 
emphysema that could be used to further test the elastase-antielastase theory of emphysema 
development or to test the potential therapeutic effect of antielastase compounds. Transgenic 
AlJ mice overexpressing Krev-l in the lung were produced in order to test its tumour suppressor 
activity which has not been tested in vivo. 
4.2 UGHNE mice 
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Superovulation of 143 SRW mice resulted in 2280 embryos being collected. Microinjection of 
the UGHNE fragment into 2082 mouse zygotes and transfer of 1195 injected embryos into 62 
recipients resulted in the birth of 87 pups (Table 4.1). 
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Table 4.1: Results of UGHNE micro injection and embryo transfer 
Numbers % 
Donors 143 
Ova 3239 23/donor 
Embryos 2280 16/donor 
Injected 2082 
Survived 1348 65% 
Transferred 1195 62% 
Recipients 62 
Pregnant 23 37% 
Born 87 7% of 
transferred 
Weaned 78 90% 
Transgenic 12 1% of 
transferred 
Transmitted 8 67% 
Out of 78 mice weaned, Southern blotting (Figures 4.1-4.5) of Barn HI-digested mouse tail 
DNA showed that 12 mice were transgenic. The UG 3.3 probe in theory can detect 2 internal 
fragments of 0.9 kb and 2.9 kb, but no integration fragment (Figure 2.1). The 2 internal 
fragments are present in 9 of the transgenic founder mice, suggesting integration without 
rearrangement. In mice 599 (Figure 4.1) and 55 (Figure 4.2) the 2.9-kb fragment is missing and 
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a larger fragment is detected by the probe. The most probable explanation for this bandBhift is 
loss of the Bam ill site at position 20 during integration (map in Figure 2.3 a). This site is 20 bp 
away from the 5' -end of the microinjected fragment and "nibbling" of the fragment before 
integration may have occurred and indeed has been described in the literature (Hamada et al 
1993). Therefore, fragments larger than 2;9 kb visible in several founder mice (599, 66, 54, 55, 
56, 1043) are probably integration fragments. Mice 54, 55 and 56 (Figure 4.2) show several 
larger fragments that may correspond to multiple integrations (discussed later in this Chapter). 
Founder mouse 1051 shows only one band of about 4 kb (Figure 4.4) that could be the result of 
gross rearrangement of the trans gene -with loss of the Bam HI site at position 2900 or 
methylation of the same Bam ill site. In addition to the 2.9-kb and the 0.9-kb band, the 10-
copy standard -showed high size bands corresponding probably to partial digest of the plasmid. 
Copy number is best estimated in non-founder animals, since GOs may be mosaic and mosaicism 
confuses copy number estimation. Southern blots were done for GIs only in Lines 596, 66, 56, 
1043, 90, and 55 (Figures 4.3, 4.5, 4.6, and 4.7); all other GIs were screened by PCR (Figure 
4.8). Copy numbers, as estimated by visually comparing the intensity of the bands in the 
transgenic mouse samples with 1 and 10 copy standards, ranged from one to ten copies. Copy 
numbers of expressing lines are given in Table 5.2, Chapter 5. 
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Southern blot of mouse tail DNA probed with 32P-IabelJed UG3.3. "Copy I" 
and "10" are non-transgenic mouse tail DNA plus the amount ofUGHNE 
that corresponds to I and 10 copies of the lransgene per mouse haploid 
genome, respectively. Control is non-transgenic mouse tail DNA. The 
probe detected a 2.9-kb and a 0.9-kb band corresponding to internal 
fragments. Four founder transgenic mice (86, 596, 599, 66) are identified in 
this blot. 
78 
79 
0>-
0>- n. 2 n. 0 
0 () -() c en CD r--
0 0 co co co 0 C'l ~ en CD r--0 en en en N en en en en en 
2.9 kb --. 
0.9 kb --. 
Figure 4.2: Southern blot of mouse tail DNA probed with 32p labelled UG3.3. I copy 
and 10 copy are non-transgenic mouse tail DNA plus the amount of UGHNE 
that corresponds to I and 10 copies of trans gene per mouse genome, 
respectively. Control is non-transgen ic mouse tai l DNA. The probe 
detected a 2.9 kb and a 0.9 band corresponding to internal fragments. Four 
founder transgenic mice (586, 54, 55, 56) are identified in thi s blot. 
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Figure 4.3: Southern blot of mouse tail DNA probed with 32P-Iabelled UG3.3. I copy 
and 10 copy are non-transgenic mouse tail DNA plus the amount of 
pUGHNE that corresponds to I and 10 copies of transgene per mouse 
genome, respectively. Control is non-transgenic mouse tail DNA. Mice 
1020-1022 are G I offspring of 596 crossed with a wild-type mouse. 1023 
and 1024 are G 1 offspring of 66 crossed with a wild-type mouse. All others 
are GO mice. The probe detected a 2.9-kb and a 0.9-kb band corresponding 
to internal fragments. Three founder (1018, 86, 90) and 4 G I ( 1020, 102 I, 
1022 Line 596; 1023 Line 66) transgenic mice are identified in this blot. 
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Figure 4.4: Southern blot of mouse tail DNA probed with 32p labelled UG3.3. 1 copy 
and 10 copy are non-transgenic mouse tail DNA plus the amount of 
pUGHNE that corresponds to I and 10 copies of trans gene per mouse 
haploid genome, respectively. Control is non-transgenic mouse tail DNA. 
All mice are GO. The probe detected a band of about 4 kb in mouse 1051 . 
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Figure 4.5: Southern blot of mouse tail DNA probed with 32p labelled UG3.3. I copy 
and 10 copy are non-transgenic mouse tail DNA plus the amount of UGHNE 
that corresponds to I and 10 copies of transgene per mouse haploid genome, 
respectively. Control is non-transgenic mouse tail DNA. 1043 is a GO 
mouse. 11 20 is offspring of S6 crossed with a wild-type mouse. All other 
micc are offspring of 1018 crossed with a wild-type mouse and are 110n-
transgenic. The smear seen in the top of each lane corresponds to non-
specific bindind as it is also present in the control DNA lane. 
83 
>-
>- 0. e 0. 0 
0 <.> c co 
<.> 0 -0 N 
-
U 
-
0.9 kb -. 
Figure 4.6: Southern blot of mouse tail DNA probed with 32p labelled UG3.3. I copy 
and 10 copy are non-transgenic mouse tail DNA plus the amount of UGHNE 
that corresponds to I and 10 copies of transgene per mouse haploid genome, 
respectively. Control is non-transgenic mouse tail DNA. All mice are G I 
offspring of mouse 1043 crossed with a wild-type mouse. The probe 
detected a 2.9 kb and a 0.9 band corresponding to internal fragments. Onc 
G I transgenic mouse is identified in this blot. 
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Figure 4.7: SOllthern blot of mouse tail DNA probed with 32p labelled UG3.3. I copy 
and 10 copy are non-transgenic mouse tail DNA plus the amount of UGHNE 
that corresponds to 1 and 10 copies of trans gene per mouse haploid genome, 
respectively. Control is non-transgenic mouse tail DNA. 1225 is G I 
offspring of mouse 90 crossed with a wi ld-type mouse. 1103 is G I offspring 
of mouse 55 crossed wi th a wild-type mOllse. 1253- 1255 are G2 offspring of 
mouse 596. The probe detected a 2.9 kb and a 0.9 band corresponding to 
internal fragments in 3 mice and a high molecular weight band in mouse 
1103 . 
Transgenic founder mice were bred with non-transgenic SRW mice to establish lines. Mice were 
screened either by Southern blotting or, in most instances, with peR (Figure 4.8). The numbers 
of G 1 transgenic and non-transgenic mice derived from each founder are given in Table 4.2. 
Table 4.2 Number offrrst generation (G1) transgenic (TG) and non-transgenic (NTG) 
mice derived from each UGHNE founder transgenic mouse. 
Line NTG TG 
54 7 5 
55 36 1 
56 17 12 
66 10 3 
86 11 5 
90 4 5 
586 2 0 
596 0 3 
599 4 9 
1018 37 0 
1043 13 1 
1051 0 0 
Total 141 44 
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Figure 4.8: 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
PCR analysis of mouse tail DNA. 
Mice screened by this PCR are founder mouse 55 (lane 13) and offspring 
of transgenic founder mouse 596 (numbers 5 to II ) crossed with a wild-
type mouse. 
Lane I is A Hind III molecular weight marker. 
Lanes 2 and 5 are DNA from transgenic mice 66 and 596, respectively 
and are used as positive controls. 
Lanes 3 and 14 are non-transgenic mouse DNA. 
Lanes 4 and 15 are blank (no DNA). 
An 879-bp UG DNA fragment is ampl ified by primers UGI and UG2 in 
transgenic mice. 
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Mouse 1051 died shortly after weaning before producing any progeny. Mice 586 and 1018 did 
not produce any transgenic offspring. Mouse 55 produced one transgenic out of 37 offspring. 
This mouse (number 1103) showed a high molecular weight band in the Southern blot (Figure 
4.7) indicating rearrangement. Founder mouse 55 showed a high molecular weight band of the 
same size as mouse 1103 in the Southern blot (Figure 4.2), also indicating rearrangement. Thus 
Line 55 was abandoned. All other 8 founder mice produced transgenic progeny. Mouse 1043 
produced one transgenic offspring out of 14. Southern blotting showed that the intensity of the 
band in the G 1 mouse was about 10 times more intense than in the founder animal. The low 
percentage of transgenic progeny and the difference in the intensity of bands between GO and G 1 
(Figures 4.5 and 4.6) show that 1043 is mosaic. A small degree of mosaicism may be present in 
some of the 7 other founder mice that produced transgenic offspring since, together, they 
produced 57 non-transgenic and 42 transgenic G 1 offspring. However, mosaicism of individual 
founders cannot be established with certainty as the number of G 1 offspring produced by each 
GO is too small. 
4.3 UGKREV and UKH transgenic mice 
The results of microinjection are shown in Table 4.3. Microinjection of UGKREV and 
transfer of 1117 AlJ embryos resulted in the birth of 33 pups, 2 of which were transgenic. 
This result is well below our usual success rate and reflects the poor breeding performance 
of this strain. The AlJ donors yielded an average of 8 zygotes per mouse, the pregnancy rate 
was only 20%, and there was a high rate of neonatal mortality. With the SRW strain, a 40% 
pregnancy rate would be expected and 1 % to 5% of all injected zygotes are expected to be 
transgenic. UGKREV and UKH were then injected into 347 (UGKREV) and 1985 
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(UKH) SRW zygotes resulting in the birth of 8 UGKREV and 9 UKH transgenic mice, 
close to these expected success rates. 
Table 4.3: Results of micro injection with UGKREV and UKH 
UGKREV in AI] UGKREV in SRW UKHinSRW 
Donors 239 30 164 
Ova 1920 8/donor 638 211donor 2655 16/donor 
Embryos 1450 6/donor 347 12/donor 2138 13/donor 
Injected 1414 341 1985 
Survived 1117 79% of 257 75% of 1233 57% of 
injected injected injected 
Transferred 1073 76% of 251 74% of 1120 56% of 
injected injected injected 
Recipients 65 15 64 
Pregnant 12 18% 7 46% 19 30% 
Born 33 3% of 28 11% 62 of 5% of 
transferred transferred transferred 
Weaned 21 63% 23 82% 52 83% 
Transgenic 2 0.14% 8 2.3% 9 0.45% 
Transgenic founder mice were identified by Southern blotting of tail DNA. Figure 4.9 shows the 
probe used for Southern blots of UGKREV mice and the sizes of the expected fragments. Ten 
UGKREV transgenic founder mice were identified, of which 2 were in in AlJ background 
(Figure 4.10) and 8 in SRW background (Figure 4.11). 
In most cases the trans gene integrated as multiple copies arranged in head-to-tail fashion 
(Figures 4.10 and 4.12), as demonstrated by the presence of a 1.6-kb band in addition to the 3.6-
kb band that corresponds to an internal fragment. Mouse 1515 showed the 3.6-kb band but not 
the 1.6-kb band, and has probably integrated only one copy of the transgene (Figure 4.12). 
Additional bands of a lesser intensity were also detected by the probe and may correspond to 
integration fragments (discussed later in this Chapter). There was no evidence of rearrangement 
of the transgene. Copy numbers cannot be estimated because Southern blotting was done only 
with the founder animals and the next generations were screened by PCR, because of budget 
restraints. Exact copy number determination in GOs is not possible because of the possibility of 
mosaicism. 
To evaluate the integrity of the UKH trans gene after integration, mouse tail DNA from 4 
founder mice was digested with Bam HI or Pst I, which produce 2 and 4 internal fragments, 
respectively (Figures 4.13 and 4.14), and used for Southern blotting. The UG3.3 probe detected 
the expected fragments (1.3 kb, 1 kb, 0.8 kb, and 0.6 kb for the Pst I digestion and 2.9 kb and 
1.8 kb for the Bam HI digestion) as well as additional faint bands that may have resulted from a 
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partial DNA digestion. Probing Pst 1- or Bam HI-digested UKH transgenic mouse DNA with 
UG3.3, however, does not show the integration fragments in the Southern blot. 
To have more insight into the pattern of integration of the UKH transgene, a Southern blot of 
Bgi II-digested DNA was performed. Figure 4.15 shows the sizes of the expected fragments in 
case of single, head to tail, head to head or tail to tail integration. Analysis of Southern blot of 
DNA from mice 2584 and 2585 showed the presence of- 16.2-kb, 8.8-kb;and 1.4-kb bands, 
demonstrating a complex integration of the transgene in head-to-tail, head-to-head and tail-to-tail 
arrangement, as well as additional· faint bands that may -correspond to integration fragments 
(Figure 4.16). 
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Figure 4.9: Integration of VOKREV into the mouse genome as a single-copy (A) 
or multiple-copy (B). 
In case of single-copy integration, a 3.6-kb internal fragment and an 
integration fragment larger than 0.7 kb are detectable by the V03.3 
probe. 
In case of head to tail tandem array integration, in addition to the 
3.6-kb and 0.7+ kb fragments, a 1.6-kb fragment is detected. 
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Figure 4.10: Southern blot of mouse tail DNA digested with BgI II and probed with 32p_ 
labelled UG3 .3. I and lO are non-lransgenic mouse lail DNA plus lhe 
amount of UGKREV that corresponds to I and 10 copies of trans gene per 
haploid mouse genome, respecti vely. Control is non-transgenic mouse tail 
DNA. Two founder transgenic mice (numbers 1798 and 1803) are identified 
in this blot. The small size band seen in the strandards corresponds to the 
700 bp of sequence between the 5' end of UG 3.3 and the first BgI II site . 
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Figure 4.11: Southern blot of mouse tail DNA digested with Bgi II and probed with 32p 
labelled UG3.3. 
I and to are non-transgenic mouse tail DNA plus the amount of UGKREV 
that corresponds to I and 10 copies of trans gene per haploid mouse genome, 
respectively. Contro l is non-transgenic mouse tail DNA. Eight founder 
transgenic mice (numbers 1507, 1509, 1512, 1513, 1514, 1515, 1518, 1520) 
are identified in this blot. 
94 
Copy Mouse number 
0 
z to f"- a:> m Cl ~ (\J (') v .., to C Cl Cl Cl Cl ~ ~ ~ ~ 
10 1 0 .., .., .., .., .., .., .., .., .., .., .., U ~ ~ ~ ~ ~ ~ 
3.6 kb_ 
-
1.6 kb_ 
Figure 4.12: Southern blot of mouse tail DNA digested with Bgl II and probed with 32p_ 
labelled UG3.3. I and 10 are non-transgenic mouse tail DNA plus the 
amount of pUGKREV DNA that corresponds to I and [0 copies of 
transgene per haploid mOllse genome, respectively. Control is non-
transgenic mouse tail DNA. Six founder transgenic mice (l507, 1509, 
151 2, l513, 1514, and 1515) are shown in this blot. The larger band in the 
standards corresponds to a DNA fragment containing 900 bp of Krev-I 3' 
sequence, 700 bp of UG3.3 5' sequence, and the vector. 
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Figure 4.13a: Map of 
pUKH with Bam HI 
restriction sites. Positions are 
approximative. 
Figure 4.13b: Map of 
pUKH with Pst I restriction 
sites. Positions are 
approximative. 
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Figure 4.14: Southern blot of mouse tail DNA digested with Pst I (first 7 lanes) or Bam 
HI (last 6 lanes) and probed with 32P-labelJed UG3.3. I , 5 and 10 copy are 
non-transgenic mouse tail DNA plus the amount of UKH DNA that 
corresponds to I , 5 and 10 copies of transgene per haploid mouse genome, 
respectively. Control is non-transgenic mouse tail DNA. Four founder 
transgenic mice (2584, 2585, 2607, 2610) are shown in thi s blot. 
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Figure 4.15: Integration of UKH into the mouse genome as a single-copy or 
multiple-copy in head to tail, head to head or tail to tail arrangements. 
The sizes of the expected bands are given for each possibility. 
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Figure 4.16: Southern blot of mouse tail DNA digested with BgI II and probed with 32p_ 
labelled U03.3. I and 10 copy are nOll-transgenic mouse tail DNA plus the 
amount of UKH DNA that corresponds to I and IO copies of transgene per 
haploid mouse genome, respectively. Control is non-transgenic mouse tail 
DNA. Two founder transgenic mice (2584 and 2585) are shown in this blot. 
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All founder UGKREV and 5 founder UKH mice were mated to non-transgenic All mice to 
generate transgenic lines. Offspring were screened for the presence of the transgene by PCR. A 
typical PCR result is shown in Figure 4.17. -Table 4.4 shows the-numbers of transgenic and non-
transgenic mice from each line. 
Table 4.4 Transmission of UGKREV and UKH transgenes. 
Gl G2 andG3 
Line Construct NTG TG NTG TG 
1507 UGKREV 7 6 28 18 
1509 UGKREV 4 4 5 3 
1512 UGKREV 5 4 2 1 
1513 UGKREV 1 3 5 4 
1514 UGKREV 14 0 0 0 
1515 UGKREV 6 1 4 6 
1518 UGKREV 9 5 11 10 
1520 UGKREV 0 2 0 2 
1798 UGKREV 9 6 0 0 
1803 UGKREV 20 24 26 12 
2584 UKH 3 4 19 27 
2585 UKH 6 3 3 1 
2607 UKH 0 0 0 0 
2610 UKH 11 11 13 13 
2709 UKH 0 0 0 0 
2744 UKH 8 0 0 0 
2747 UKH 0 0 0 0 
2753 UKH 0 0 0 0 
2757 UKH 0 0 0 0 
Total 103 73 118 100 
100 
1 2 3 4 5 6 7 8 9 1011 12131415 
Figure 4.17: PCR analys is of mouse tail DNA. 
Mice screened by thi ~ PCR are offspring of transgenic founder mice 
151 3 (numbers 6 to II ) and 15 14 (12 to 15) crossed with a wi ld-type 
mouse. Lane I is t.. Hind III molecular weight marker. Lanes 2 and 5 are 
DNA from transgenic mice 15 13 and 1514, respectively and are used as 
positive controls. Lane 3 is non-transgenic mouse DNA . Lane 4 is blank 
(no DNA). An 879 bp UG D A fragment is amplified by primers UG I 
and UG2 in transgenic offspring . 
• 
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All UGKREV founder mice transmitted the transgene to their progeny, except for mouse 1514 
which produced 14 non-transgenic offspring. Of 5 UKH mice that were mated, 3 transmitted the 
trans gene, one produced 8 non-transgenic offspring and one male (2709) was sterile. From all 
lines, 103 wild-type and 73 transgenic fIrst generation (Gl) mice were produced suggesting 
mosaicism of some of the founders. Table 4.5 shows the percentages of transgenic and wild-
type mice across 3 generations, all lines combined, showing stability of transgene inheritance. 
Table 4.5 Percentages of UGKREV and UKH transgenic and wild type mice across three 
generations. 
NTG TG 
Gl 58% 41% 
G2 53% 47% 
G3 56% 44% 
4.4 Discussion 
The identity of the 3 DNA constructs used for microinjection, UGHNE, UGKREV, and 
UKH, was verified by restriction digestion with at least 2 enzymes but not by sequencing. 
Sequencing constructs of the size of, for example, UKH (8.8 kb) is not a trivial task. Most 
investigators do not sequence their constructs before using them to produce transgenic 
animals. 
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While it is a good practice to test constructs for expression in tissue culture before making 
transgenic mice, there are no cell lines that readily express UG-based constructs. 
Expression of UG-driven genes in tissue culture has been reported ( Suske et al 1992) but 
expression was weak and we were unable to reproduce their results in this laboratory. We 
are currently exploring the feasibility of liposome-mediated DNA transfer to the lungs, via 
the trachea, as a way of testing constructs for appropriate expression in the lungs, before 
generating transgenic mice. Until then, we have no choice but to produce the transgenics 
without prior knowledge of whether expression will occur. 
The efficiency of microinjection (transgenicmiGeproduced per zygote injected) when SRW 
zygotes were used was 2.3 % for UGKREV, 0.45 % for UKH and 0.58% for UGHNE. It 
is generally accepted that 1 to 5 % of microinjected mouse embryos develop into transgenic 
pups. The percentage of integrations per live pup has been reported to be as high as 25% 
(Brinster et al 1985) and 39% (Grosschedt et al 1984). Fifty to eighty percent of microinjected 
embryos survive the microinjection and 10 to 30% of microinjected transferred embryos survive 
and develop into pups (Hogan et al 1986). Our results with microinjection of UGKREV are 
within these norms. The success rate of microinjection with UKH was below the acceptable 
norms and reflects the lack of experience of the technician who did most UKH micro injections, 
who was being trained as she did them. 
Microinjection of UGKREV in 1414 AlJ mouse embryos resulted in the birth of 2 transgenic 
mice (0.14 %). The AlJ yielded an average of 8 zygotes per mouse, the pregnancy rate was very 
low at 20 % and there was a high rate of neonatal mortality. These figures reflect the very poor 
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breeding performance of the All strain, which is characterised by small litter size and high 
neonatal mortality. 
In most cases, multiple copies of the trans gene integrated, as shown by the intensity of the bands 
in the Southern blot-which were stronger than the 1 copy standard. In most cases, there was no 
gross rearrangement of the trans gene, since the bands corresponding to internal fragments were 
present and had the expected size. The number of integration sites is more difficult to determine. 
Several mice showed faint bands in addition to the internal fragments on the Southern blot which 
may correspond to integration fragments. However, they may also correspond to partial 
digestion of the DNA. Multiple integration can be demonstrated only if the GIs show several 
different restriction patterns. Since screening of GIs was, with a few exceptions, done by peR, 
because of time and budget constraints, it is not possible to determine whether multiple 
integration had occurred. 
The majority of transgenic founder mice transmitted the trans gene to their progeny. 
Occasionally all progeny of a transgenic founder mouse appeared to be non-transgenic. 
This happens when the founder animal is mosaic, ie does not have the trans gene in all its 
cells. The trans gene is present in cells included in the tail biopsy that was used to 
determine the transgenic status of the mouse, for example the skin or the bone, but not in 
the germ line, hence the lack of transmission. Mosaicism also resulted in transmission to 
less than 50 % in some lines. For example, in Line 1403, only 1 G lout of 14 was 
transgenic, suggesting that the trans gene was present in only a fraction of the germ line 
cells. Mosaicism is due to late integration of the transgene, when the embryo has already 
divided. 
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Mosaicism was also reported by Wilkie et al (1986) who examined 262 transgenic mouse 
pedigrees and found that 30% of mice produced by microinjection of one-cell embryos were 
mosaic in the germ line. 
One UKH male founder mouse (number 2709) was sterile. The animal was copulating 
normally as demonstrated by the presence of vaginal plugs in the females with whom he was 
mated, but was azoospermic as demonstrated by total absence of sperm in semen recovered 
from the genital tract of those females. This azoospermia could be dueto expression of 
UKH in the male germ line, to disruption of a gene essential for spermatogenesis by 
integration Dfthetransgene, or toa cause totally unrelated to the transgene. Unfortunately, 
the mouse died before these possibilities could be explored. 
4.5 Summary 
Transgenic mice were produced with 3 different constructs. 
pUGHNE was constructed by cloning a genomic fragment containing the entire HNE 
coding region downstream from UG3.3. Microinjection of UGHNE into SRW mouse 
embryos resulted in the birth of 12 transgenic mice from which 8 lines of transgenic mice 
were bred. 
pUGKREV was constructed by cloning a human Krev-l cDNA downstream from UG3.3. 
Microinjection of UGKREV into AlJ mouse embryos resulted in the birth of 2 transgenic 
mice whereas injection of the construct into SRW mouse embryos resulted in the birth of 8 
transgenic mice. All but one founder animals transmitted the transgene to their offspring. 
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pUKH was constructed by cloning a mutated, more potent human Krev-l cDNA 
(Krev-l(Glu63» downstream from UG3.3, then cloning a genomic fragment containing the 
HNE coding region without the translation start site downstream from Krev-l (Glu63). Nine 
founder mice were produced, 5 were mated from which 3 lines of transgenic mice were 
derived. 
Transgenesis was demonstrated by Southern blotting which showed that in most transgenic 
mice, multiple copies of the trans gene have integrated, with no gross rearrangement of the 
transgene. Further proof of transgenesis was given by PeR-amplification of an 879-bp 
fragment from offspring of founder mice using UG-specific primers. 
The overall number of transgenic G 1 mice was 117 whereas the number of non-transgenic 
G 1 mice was 244 suggesting mosaicism in several founder mice. Mosaicism is often 
observed in transgenic GO mice (Wilkie et al 1986) and is generally considered to be an 
imperfection of the technique of transgenesis rather than due to toxicity of the injected 
DNA. Transmission from all but GO mice was in a Mendelian fashion. 
In conclusion, with all 3 constructs used the trans gene integrated in most founder mice 
without gross rearrangement and was transmitted to up to 3 generations in a Mendelian 
fashion. Thus these mice were suitable for further experimental studies. 
Results 
ChapterS 
Pulmonary Expression of Human Neutrophil 
Elastase in Transgenic Mice 
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TIlls chapter describes transgenic mice expressing the human neutrophil elastase gene in their 
lungs under the control of the rabbit uteroglobin promoter, which were produced in an attempt 
to produce an animal model for emphysema and to further test the elastase-antielastase theOlY. 
5.1. Transgeneexpression 
5.1.1 RNA expression 
Eight lines of transgenic mice were established from mice that transmitted the transgene to their 
progeny and were analysed for transgene expression. All 8 lines were tested for HNE expression 
in 14 organs. From each line, every organ except the lung was tested once. Two mice from 
each line were sacrificed so that RNA from inale and female genital tracts could be extracted. 
The other organs came either from the male or the female, depending on the line. In four lines, 
the lungs were tested more than once (Table 5.1). Analysis of total RNA by Northern 
hybridisation showed strong expression of HNE in the lungs of transgenic mice in 6 out of the 8 
lines and weak expression in one line (56) (Figure 5.1). In the 8 lines of transgenic mice, no 
HNE mRNA was detected in 13 other tissues (eg Figures 5.2 and 5.3), except for weak signals 
from spleen (lline, Figure 5.4) and uterus (1 line, Figure 5.5). A weak signal was also detected 
in bone from transgenic and control mice (Figures 5.3 and 5.4) and probably corresponds to 
endogenous mouse neutrophil elastase (neutrophil elastase is expressed in the bone marrow). 
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Figure 5.1: NOlthem blot of total RNA (20 Ilg) fi'om lungs of transgenic mice fi'om 8 
independent lines probed with a 32P_labelled HNE cDNA. + control is RNA from 
cell line U937 which expresses high levels of HNE. Non-transgenic is non-
transgenic mouse lung RNA. Line 56 showed weak expression after longer 
exposure. 
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Figure 5.2: NOlthem blot of total RNA (20 flg) from various tissues of 2 transgenic mice 
from line 86 probed with a 32P-labelled HNE cDNA. + control is RNA from cell 
line U937 . NT lung and NT bone are non-transgenic mouse lung and bone RNA, 
respectively. S. Vesicle: seminal vesicle. S. gland: salivary gland. 
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Figure 5.3: Northern blot of total RNA (20 ~g) from various tissues of a transgenic mouse 
from line 66 probed with a 32P-labelled HNE cDNA. 
Control is RNA from a wild-type mouse. Sal. Gland: salivary gland. 
The probe detected a strong l.3-kb band in the lungs and a weak signal in 
control bone. Two weak bands of a higher molecular weight are also 
visible in all tissues and cOlTespond probably to non-specific binding of 
the HNE probe to ribosomal RNA. 
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Figure 5.4: NOIthem blot of total RNA (20 Ilg) from various tissues of transgenic mice from 
line 90 probed with a 32P_labelied HNE cDNA. 
Control is RNA from a wild-type mouse. Sal. Gland: salivary gland. 
The probe detected a signal in spleen and transgenic and wild-type bone but not 
in the lungs. 
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Figure 5.5: NOlthern blot analysis of total RNA extracted from the reproductive 
tract of transgenic mice from various lines probed with a 32P-Iabelled 
HNE cDNA. 
The line of u'ansgenic mice and the organ from which RN A was extracted 
are indicated above the lanes. U937 is positive control. 
Sem. ves.: seminal vesicle. Only line 1043 uterus and the positive 
control show a positive signal. 
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5.1.2 Penetrance of transgene expression in the lung 
To test for the penetrance of transgene lung expression, several individual Gland G2 mice from 
each expressing line were tested for expression, either by Northern blotting or by ELISA (Table 
5.1). In all expressing lines,- expression in thelung-s was detected in all animals tested, suggesting 
a 100% penetrance of trans gene lung expression .. 
Table 5.1: Number of transgenic mice from each line tested for HNE expression in 
the lungs by Northern blotting or ELISA. 
Animals tested by Animals tested by 
Northern blotting ELISA 
Line 
54 1 2 
56 1 2 
66 1 5 
86 3 7 
90 2 0 
596 2 3 
599 3 2 
1043 1 2 
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5.1.3 Detection of the protein 
Immunohistochemistry with specific anti-HNE antibody indicated the presence of HNE protein 
in the bronchial epithelium (Figure 5.6). Staining of the epithelial cells was continuous and 
appeared to be confined to the surface of the epithelium. No obvious staining of the cytoplasm 
of cells forming the bronchial epithelium was detected. Staining may con'espond so secreted 
HNE, maybe by a few cells, that diffused at the epithelial sUlface. The presence of HNE protein 
in the alveolar cells, where a very faint brown colour was visible, is questionable. Secretion of 
HNE was confirmed by ELISA of bronchoalveolar lavages from transgenic mice (Table 5.2). 
The concentration ofHNE in lavage fluids from the 6 highly expressing lines-in terms of mRNA 
varied from 275 nglml in line 66 to 9 nglml in line 599 and no HNE protein was detected in the 
weakly expressing line (Line 56). Pmtein expression was detected in every mouse tested in all 
expressing lines. There was no obvious correlation between the level of HNE protein expression 
and transgene copy number (Table 5.2) 
Table 5.2: HNE protein concentrations in bronchoalveolar lavages from transgenic mice. 
Line N HNE nglml (mean ± SD) Copy number 
66 5 275 ±50 3 
1043 2 140±28 10 
86 7 120± 84 ND 
596 3 103 ± 69 5 
54 2 75±35 ND 
599 2 9±2 ND 
56 2 0 3 
Non-transgenic 2 0 NA 
ND: not determined. NA: not applicable 
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Figure 5.6: Immunoperoxidase staiJUng with anti-HNE of sections from lungs of a transgenic 
mouse (A) and a non-transgenic littennate (B). Counter-stained with 
haematoxyJin. Magnification: x200. 
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Concentrated bronchoalveolar lavages were passed over a CM-cellulose column and the 
fractions were analysed by dot blot using specific anti-HNE antibodies. HNE was detectable in 
the 1.0 M salt elution fraction ofthe lavages (Figure 5.7). A positive signal was detected in all 4 
samples from transgenic mice from 3 different lines. -Two lavages from non-transgenic 
littermates did not show any signal whereas a faint signal was visible in one non-transgenic 
lavage (Line 54) which could be due to contamination. Western blots of CM-cellulose column-
purified lavage fluid pooled from 5 mice (Figure 5.8) showed two bands in both the wash and 
salt-eluate fractions at about 30 Kdin transgenic but not in non-transgenic samples. The two 
bands correspond to pure HNE, with the small difference between the two band sizes being due 
to a difference in the numbers of carbohydrate side chains (Takahashi et al 1988a). In the wash 
fraction (Figure 5.8) there was also a larger band of approximately 80 Kd which probably 
represents an elastase-inhibitor complex. 
5.2 Elastase activity 
Using an activity assay, no HNE activity was detected even in lavage samples containing 100 ng 
of immunoreactive HNE (measured with ELISA), even though the activity of a positive control 
containing 300 pg of pure HNE was easily detected. 
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• 
200ng 100ng 50ng 20n9 10n9 
1 000 n9 
54 NTG 54 TG 596 NTG 596 TG 
596 TG 66 NTG 66 TG 
Figure 5.7: Dot blot analysis of eM-cellulose pUlified bronchoalveolar lavages analysed 
with an anti-elastase antibody. 
Top 2 rows are various amounts of purified HNE. 
Bottom 2 rows are bronchoalveolar lavage fluid from transgenic (TO) and non-
u·ansgenic (NTO) mice 
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Non-transgenic Transgenic HNE 
II II 
- Complex 
- Free HNE 
Figure 5.8: Westem blot of bronchoalveolar lavages. Elution and wash refer to matelial 
bound and unbound to CM-23 COIUlTU1, respectively. TG=transgenic, NTG=non-
transgenic. 
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Lack of detectable active enzyme due to complex fOlmation is supported by assay of the lavage 
fluid for inhibitory activity. Lavage fluids were incubated with putified elastase in the presence of 
the elastase chromogenic substrate and elastase activity was measured (Bieth et ai, 1974). 
Various amounts of putified AAT were used as standards. Assay of lavage fluids from 9 mice 
from 3 different lines revealed levels of 2000-5300 ng/ml AAT-equivalents (Table 5.3). 
Table 5.3: Level of HNE inhibitory capacity in BAL of transgenic mice. 
Line Mouse HNE inhibitory capacity 
ng AAT eq/ml lavage 
596 1246 2700 
596 1248 5300 
596 1250 4600 
596 1255 5000 
596 1256 5000 
596 1257 2000 
66 1266 4400 
66 1269 2700 
54 1075 3100 
NTG 1253 3500 
NTG 1074 5900 
NTG: non-transgenic 
This amount of inhibitor(s) was approximately lO-fold greater than that of HNE (Table 5.2). 
Thus, in all mice tested, there was an excess of AAT that probably masked the activity of HNE. 
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5.3 Histology 
Transgenic mice from all expressing lines were examined for histological signs of emphysema 
and compared with age-matched non-transgenic mice. The sections were examined and the 
morphology of the lung described by an independent pathologist without prior knowledge of the 
transgenic status of the mice; The· histology was then classified into 3 grades. 
Grade 0: no sign of emphysema. 
Grade I: mild or focal subpleural increase in alveolar size. 
Grade 2: marked or extensive subpleural increase in alveolar size. 
There were no signs of fibrosis or gross alteration in lobar morphology. Grade 2 is consistent 
with mild emphysema whereas grade 1 was more difficult to interpret. Obviously, grade 0 is no 
emphysema. Examples of grade 0, I and 2 are shown in Figure 5.9. 
No signs of emphysema were detectable in transgenic mice up to 11 months old (all mice were 
grade 0). Animals older than 12 months, however, had grade 1 and grade 2 histology, as well as 
grade 0, both in the transgenic and age-matched non-transgenic groups (Table 5.4). 
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Figure 5.9: Grading of emphysema 
Light microscopy of lung sections from transgenic mice, stained with 
haematoxilin-eosin, Magnification: x 40, 
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Table 5.4: Incidence of emphysema in transgenic (TG) mice and non-transgenic (NTG) 
littermates at 12 months and older. 
Line 66 86 1043 54 TG NTG 
Grade 
° 
6 5 1 
° 
12 (33%) 3 (9%) 
1 9 3 5 2 19 (53%) 26 (76%) 
2 2 1 1 1 5 (14%) 5 (15%) 
Total 17 9 7 3 36 34 
The figures are numbers of mice with grade 0, I-or 2 histology. Numbers given in columns 66, 
86, 1043, and 54 are numbers of transgenic mice for each line with grade 0, grade 1, or grade 2 
emphysema. Numbers in TO column are total numbers of transgenic mice from the 4 lines 
examined with grade 0, grade 1, or grade 2 emphysema. Percentages are given between 
brackets. 
The results in Table 5.4 show that there is no increase in the incidence of marked emphysema in 
the transgenic group. Expression of HNE in the lungs of transgenic mice did not result in mice 
developing emphysema. 
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5.4 Discussion 
Eight lines of transgenic mice were produced, 6 of which strongly expressed HNE in the lungs, 
one expressed weakly and one did not express any detectable HNE. The presence of the protein 
was detected by ELISA and immunohistochemistry with HNE-specific antibodies. Variation of 
transgene expression between lines has been reported (Clark et al1994) and was attributed to 
position effect. Lack of expression in some lines is explained by integration of the trans gene in 
an inactive region of the genome which has a negative influence on transgene expression. 
Despite detection of HNE by ELISA, no HNE activity could be detected in the bronchoalveolar 
lavages. There are two possible explanations for the absence of HNE activity in the 
bronchoalveolar lavages. One possibility is that HNE is not correctly processed by the bronchial 
epithelial cells and is secreted in an inactive form. HNE is initially synthesised as an inactive 
pre-pro-protein (Figure 5.10). As is the case with other serine proteases (Neurath 1984), it is 
probable that removal of the N-terminal Ser-Glu pro peptide is essential for the activation of this 
enzyme. Mouse bronchial epithelial cells may not have the enzymatic mechanism necessary for 
cleavage of the human pro-peptide. The second, and more likely, possibility is that enzyme 
-~ activity is masked by binding to an anti-elastase. This possibility is supported by the presence of 
the 80-Mr band shown in Figure 5.8, which corresponds to the Mr of an elastase-at-antitrypsin 
complex. The HNE-AAT complex is essentially irreversible, with a Ka of approximately 107 M~t 
sec~l, and does not dissociate even on denaturing gels (Travis and Salvensen, 1983). While it is 
not known whether it is the case with AAT,other trypsin inhibitors, such as Aprotinin, will form 
a complex only with active HNE and not with the proenzyme (Salvesen and Enghild 1990). 
Thus, the complex at 80 Mr can be taken as evidence for the secretion of active HNE. 
1'1 •••• 
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Figure 5.10: Organisation of the human neutrophil elastase. 
The numbers of residues are indicated. 
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At physiological concentrations, the half-time for association is approximately 0.6 msec (fravis 
and Salvensen, 1983) and, therefore, HNE activity cannot be detected in the presence of 
inhibitor. 
The fact that the lavage contains-protein corresponding to purified HNE (Figure 5.8) but activity 
could not be detected may be explained by incomplete processing of the proenzyme, which 
differs in only two amino acid residues from the active fonn and would not be distinguishable in 
Figure 5.8. Alternatively, the activity of this material in the lavage may have been concealed by 
binding to low molecular weight secretory leukoprotease inhibitor (Abe et al 1991), which has 
dissociated during fractionation. The Ka of SLPI is about 105 M-1 sec-I (Renesto et al 1993). 
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The reason for lack of emphysema is not clear but several possibilities exist. One explanation is 
that the levels of HNE expression were not high enough. It is very difficult to compare the levels 
of HNE in BALs from human smokers who develop emphysema and transgenic mice. In a study 
by Ochinio et al (1991) 5 X 50 ml of saline were injected in the lung of humans with on average 
120 ml recovered. The levels of HNE in non-concentrated lavage fluid were 1.15 ng/ml for non-
smokers and 0.69 ng/ml for smokers. This unexpected lower level in smokers was not found 
when the levels of HNE where expressed as ng per mg albumin suggesting that the difference 
was due to a somewhat poorer recovery or mixing of the instilled saline with the epithelial lining 
fluid in smokers. If we assume that there is 2000 times more bronchoalveolar fluid in a human 
than in a mouse (based on the body weight of a human being 60 kg and that of a mouse being 
30g) and given that about 50 times more saline has been instilled in the human lung than in the 
mouse, we can conclude that the total protein content of broncho-alveolar fluid of humans in the 
experiment described by Ochinio et al is about 40 times more concentrated than that of 
transgenic mice in this experiment. Despite the mouse bronchoalveolar fluid being more dilute, 
the HNE protein concentration in transgenic mouse BALs ranged from 9 ng/rnl to 275 ng/ml 
(compared with 0.69 ng/rnl in human smokers) suggesting that the level of HNE expression in 
transgenic mice alone does-not explain the lack of increase in the incidence of emphysema in 
these animals. As discussed above, we do not have a direct proof that HNE is active in the 
lungs of transgenic mice. The best evidence we have from the Western blot suggests that only a 
fraction of secreted HNE is active. Exactly what percentage of total HNE this active fraction 
represents remains unknown. 
It is also possible that the lifetime of a mouse is not long enough for emphysema to develop, 
knowing that in humans it takes 10 to 15 years of smoking for the disease to develop. However, 
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this hypothesis is not very likely, because about 15% of all mice (transgenics and controls) do 
develop emphysema. 
Finally there is the possibility that increased levels of elastase do not cause emphysema at all. 
Although disruption of the· elastase .. antielastase equilibrium is the current hypothesis for the 
pathogenesis of emphysema (Janoff 1986), this theory has been disputed on the grounds that 
the imbalance between elastase and its inhibitor has been clearly demonstrated to be the cause of 
emphysema only in patients with a.1-antitrypsin deficiency, which represent only 1 % of all 
patients with pulmonary emphysema (0' Amiento etalI992), and that elastase activity has never 
been demonstrated in the lungs of cigarette smokers who represent the vast majority of 
emphysema. patients (CarrelLet al 1986) .. Moreover, transgenic mice expressing collagenase in 
the lungs were shown to develop emphysema (D' Amiento et al1992) and the authors suggested 
that other proteinases should be considered as the possible aetiology of the human disease. Our 
data are in line with those of D' Amiento et al (1992), and also suggest that other models for the 
development of emphysema should be considered. 
Chapter 6 
Reduction of tumour multiplicity in transgenic 
mice expressing human Krev-l in the lungs 
Results 
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This chapter describes transgenic mice expressing the human Krev-l gene in their lungs under 
the control of the rabbit uteroglobin promoter, in order to test the tumour suppressor activity of 
Krev-l in vivo. 
6.1 Transgene expression 
Microinjection of UGKREV resulted in 8 transgenic mice in SRW background and 2 transgenic 
mice in NJ background. Microinjection of UKH resulted in 9 transgenic mice in SRW 
background. 
6.1.1 Northern blotting 
We initially attempted to test for trans gene expression by Northern blotting. A human Krev-l 
cDNA probe used with mouse lung RNA detected 3 bands of approximately 3.0,2.4 and 1.8 kb 
in transgenic animals and non-transgenic littermates, which probably all correspond to various 
members of the ras gene superfamily that cross hybridise with the Krev-l probe (Figures 6.1). 
The 3.0-kb and the 1.8-kb bands were also visible in RNA from brain, spleen, lung, and liver of a 
transgenic mouse from line 2585, in RNA from brain, testis, prostate, lung, seminal vesicle, and 
liver of a transgenic mouse from Line 2610, and in RNA from human cell line U937 (Figure 6.2). 
The 2.4-kb band was faint and appeared inconsistently. The 1.8-kb band was the most intense 
and wall about the size of Krev-l mRNA (discussed later in this chapter). 
3 kb 
2.4 kb 
1.8 kb 
1507 1798 
I II I 
NTG TG NTG TG 
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Figure 6.1: NOlthern blot analysis of lung total RNA from UGKREV transgenic mice and 
non-transgenic littelmates probed with a 32P_labelled Krev-l cDNA. 
TG: transgenic. NTG: non-transgenic. The numbers above the lanes indicate 
the line of transgenic mice. Three major bands are detected by the probe with no 
obvious difference between transgenic and non-transgenic animals. 
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Figure 6.2: NOlthem blot of total RNA extracted from several organs from 2 lines of UKH 
transgenic mice probed with a 32P.labelled Krev- I cDN A. 
NTG lung is non-transgenic mouse lung RNA. S. vesicle is seminal vesicle. The 
numbers above the lanes indicate the line of transgenic mice. 
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There was no significant difference in intensity between transgenic and non-transgenic groups. 
Northern blot probed with Krev-1 was therefore inconclusive as to whether transgenic Krev-1 
was expressed in the lungs. 
In order to distinguish between transgenic and endogenous expression, we probed a Northern 
blot of UKH transgenic mouse RNA with a HNE cDNA. The UKH transgene includes HNE 
sequence which should be transcribed into mRNA because there is no polyA signal in the 3' end 
of the Krev-1 fragment used to make the construct. HNE would not be translated, however, as 
there is a stop codon in the Krev-1- fragment and the translation start codon of HNE has been 
removed (Figure 2.3). Analysis of RNA from lung, uterus, spleen, brain, and liver from a 
transgenic-mouse from line 2610 showed 2 bands of about 0.9 and 1.35 kbin RNA from the 
lung (Figure 6.3). Similar analysis by Northern blotting of RNA from 6 different tissues from a 
transgenic mouse from line 2584 showed a very faint band of about 1.35 kb in the lung (Figure 
6.4). The expected size of the Krev-HNE transcript is 1.9 kb. The smaller size and the presence 
of two bands suggest alternative splicing of the transcript. The intensity of the 2 bands is much 
weaker than expected as in our experience UG-driven transgenes are strongly expressed in the 
lungs ( DeMayo et at 1991b and Figure 6.3). As shown in Figure 6.3, RNA from lungs of a 
UGHNE transgenic mouse (see Chapter 5) gives a much more intense signal than lung RNA 
from UKH mice. When a Krev-1 probe was used with UKH transgenic mice RNA (lines 2610 
and 2585), the 1.35 kb and the 0.9 kb bands were not present (Figure 6.2) suggesting that the 
Krev-1 probe is less sensitive than the HNE probe. 
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Figure 6.3: NOIthem blot analysis of RNA D'om various organs from a UKH transgenic mouse 
(line 2610) probed with a HNE cDNA. 
A strong signal is detected in RNA from cell line U937 and in RNA D'om lungs 
of a transgenic mouse expressing HNE in the lungs (UGHNE). Two bands of 
moderate intensity are present in the UKH transgenic mouse lung. 
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Figure 6.4: NOlthem blot analysis of RNA from vatious organs from a UKH transgenic mouse 
(line 2584) probed with a HNE cDNA 
A very faint batld is present in transgenic mouse lung RNA 
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Thus, Northern blotting showed that there was weak expression of the trans gene in the lungs of 
UKH mice, with possibly, alternative splicing and was inconclusive for UGKREV mice. 
Therefore, Ribonuclease protection (RP A) assay was used. 
6.1.2 Ribonuclease protection assay 
This method is known to be more sensitive than Northern blotting, and, in certain circumstances, 
may allow discrimination between the transgenic and the endogenous message (Damak et al 
1996). 
6.1.2.1 Optimisation of RPA 
The qUality of RPA results varies with the probe used. The concentration of RNase, the 
digestion temperature and the probe concentration are the main parameters to be considered 
during RPA optimisation. A too high concentration of RNase may result in double-stranded 
RNA hybrids being digested, whereas if the concentration is too low single stranded 
unhybridised probe may remain undigested and result in high background. A high digestion 
temperature may melt the double-stranded RNA hybrids which are then digested by the RNase, 
whereas if the temperature is too low the enzyme may not work efficiently. The results of the 
optimisation experiment are shown in Figure 6.5. The recommended concentration of 0.5 U 
RNase A and 20 U RNase TI per 220 ~l resulted in a degraded Krev-l band. The optimal 
concentration was lOX lower. There was no difference between RNase digestion at 30°C or 
37°C. When 103 cpm of probe were used instead of 104 no bands were visible. Digestion with 
0.05 U RNase A and 2 U RNase Tl, at 37°C and 104 cpm probe gave satisfactory results and 
these conditions where used for all the subsequent RP As. 
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The given RNase dilutions are dilutions of the stock solution from the RP A kit. 
A dilution of 11100 cOll'esponds to 0.5 unit RNase A and 20 units RNase Tl. 
TG: transgenic mouse lung b'om line 1803. NTG: non-transgenic mouse lung. 
The temperature of the RNase digestion is given. 
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6.1.2.2 Results of RPA analysis of transgenic mice 
RPA analysis of RNA from 12 tissues from two transgenic mice from line 2610 (UKH 
transgenotype) showed a protected band of the expected size (620 nt), corresponding to human 
Krev-l mRNA, as well as smaller bands (Figure 6.6). After overnight exposure, the 620 nt band 
was only visible in RNA from the transgenic mouse lungs and was not present in any of the 
other tissues from the transgenic mice, except in the spleen in one line (Figure 6.7). Longer 
exposures of the gel revealed a very faint band of z 600 bp in most tissues including non-
transgenic mouse lung, but not in the yeast RNA control, which probably corresponds to the 
mouse endogenous Krev-l (Figure 6.6). RPA analysis was also perfonned on lung RNA from 
six transgenic mice from six different lines (3 lines -with each-construct) in order to compare 
expression levels (Figure 6.8). Two out of three UGKREV lines and 3 out of 3 UKH lines 
expressed the transgene in their lungs. Expression was stronger in the 2 UGKREV lines than in 
UKH lines. The RPA also showed a band of approximately 500 bp that was present in all UKH 
mice analysed but not in the UGKREV lines, again suggesting alternative splicing of transgene 
mRNA in UKH mice. 
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Figure 6.6: RP A analysis of RNA from various tissues from a UKH transgenic mouse (line 
2610) using a Krev-l probe. The membrane was exposed for 3 days to XAR X-
ray film. The trans gene is expressed specifically in the transgenic mouse lungs 
(strong band) whereas endogenous Krev-l is expressed in most tissues (faint 
band). The lane labelled Krev cOlTesponds to sense Krev-l RNA synthesised in 
vitro and mixed with non-transgenic mouse lung. Control is RNA from a non-
transgenic mouse lung. 
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Figure 6.7: RPA analysis of RNA from vru~ous tissues from a UGKREV trrulsgenic mouse (line 
1803) using a Krev-I probe. 
The membrane was exposed for 7 days to XAR X-ray film. The trrulsgene IS 
expressed mainly in the transgenic mouse lungs (strong band) but also in the 
spleen (weaker band). Controls are RNA from a non-transgenic mouse lung and 
skin. The velY faint brulds present in most tissues cOITespond to endogenous 
Krev-l. 
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Figure 6.8: Analysis of Krev-l lung expression in several lines of transgenic mice 
by RPA. 
The numbers above the lanes indicate the line of transgenic mice. Krev is 
as in Figure 6.6. Probed with Krev-l and actin. One-day exposure. 
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The RP A also revealed smaller bands of about 200 bp that probably correspond to Krev-l-
related genes; they do not correspond to Krev-l because of their smaller size. The 'RP A was 
done under non-stringent conditions (low concentration of RNase) that did not cleave the mouse 
endogenous Krev-l - human probe RNA hybrid, despite possible mismatches between the two 
. molecules, resulting in the ==600 bp protected band visible after long. exposure .of the gel. 
Moreover similar small bands are present in human cell line U937 RNA (Figure 6.9) where, if 
Krev-l mRNA was present, there would have been a pelfect match between the human probe 
and Krev-l in the RNA sample resulting in a 620 bp band, as is the case with the Krev-l positive 
control. 
Expression in the lungs was consistent in mice fromthe same line. Either 3 mice (Lines 1507, 
2584, 2585, 1518) or 4 mice (Lines 1803 and 2610) from each line were tested for expression. 
All 3 mice from line 1507 did not express the trans gene in the lungs whereas all other mice 
expressed consistently. 
6.2 Tumour counts 
Transgenic mouse lines with a predominantly NJ background were derived by crossing SRW 
transgenic males with NJ females, and crossing transgenic 01 males with NJ females to 
produce 02 offspring of75% NJ genotype. One pure line (1803) was derived by mating an NJ 
transgenic male with NJ females. 
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To test the effect of Krev-1 overexpression on lung tumour multiplicity, NJ mice from 1 
UGKREV line (1803) and mice with 75% NJ background from 2 UKH lines (2610 and 2584) 
were given ethyl carbamate and, after 16 weeks, the resulting lung tumours were counted. 
Overall, there was a 20 % reduction of tumour numbers in transgenic mice compared with non-
transgenic littermates (21.7 ± 1.3 versus 26.9 ± 1.3, mean ± s.d., p<o.01). In Line 1803 
(UGKREV in NJ background), there was a 13% reduction in tumour numbers per mouse in the 
transgenic group (p<O.05). Transgenic mice from line 2584 (UKH transgene in SRW 
background) also had a significant reduction (35%, p<o.05) in the number of lung tumours 
whereas the second UKH line (line 2610) analysed for tumour multiplicity showed a non-
significant difference (8% reduction, p=O.57) (Table 6.1 and Appendix 4). The reduction in 
tumour numbers seen consistently across the 3 lines and the high level of statistical significance 
of the overall reduction demonstrate that Krev-l has a tumour suppressor activity in vivo. 
141 
Table 6.1: Counts of lung tumours per mouse after ethyl carbamate injection 
Construct UKH UGKREV Total 
Line 2584 2610 1803 
(background) SRWxNJxNJ SRWxNJxNJ NJ 
TG NTG TG NTG TG NTG TG NTG 
Number of mice 10 7 13 10 12 14 35 31 
Tumours/mouse 22.0 34.6 21.1 23.0 21.1 24.2 21.7 26.9 
(mean±SD ±3.7 ±3.8 ±2.2 ±2.4 ± 1.0 ±0.9 ± 1.3 ± 1.3 
P 0.044 0.57 0.041 0.007 
TG: transgenic; NTG: non-transgenic. 
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6.3 Histology 
To find out whether the reduction in tumour number was due solely to a decrease in papillary 
tumours, we examined lung sections from transgenic mice and non-transgenic littermates. One 
litter of eight mice from line 1803 (UGKREV in AlJ) was given ethyl carbamate at 6 weeks of 
age and the lungs examined 16 weeksmier the injection. After counting all visible tumours at 
the surface of the lungs, the tumours were dissected individually, counted, fixed, and sectioned. 
The sections were examined by light microscopy and the tumours were classified in a blind study 
by an independent pathologist as papillary or alveolar, according to Kauffman and Sass (1979). 
Tumours were classified. as papillary if they were well-delimited, compressed the surrounding 
lung tissue, and had a papillary structure; or alveolar if they were solid and tended to invade the 
surrounding alveolar spaces without causing any compression. Both types of tumours, as well as 
tumours that could not be assigned to either of the two groups, were present in all mice .. The 
tumours that could not be classified had features of both alveolar and papillary tumours. For 
example some tumours had a solid morphology but were compressing the surrounding tissues. 
Others had areas of solid architecture and papillary areas. The total numbers of tumours visible 
at the surface of the lungs and the numbers sectioned are given in Table 6.2. 
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Table 6.2: Numbers of tumours seen at the lung surface and numbers sectioned. 
Mouse Tumours visible Tumours sectioned 
3279 23 12 
3280 18 9 
3281 22 13 
3282 23 9 
3283 16 13 
3284 21 13 
3285 23 14 
3286 17 14 
Mean 20 12 
All visible tumours were dissected. However, it was technically difficult to get a tissue section 
containing all the dissected tumours and we accepted that sections containing on average 60% of 
the total number of dissected tumours was a representative sample of the total tumour 
population of a given mouse. The papillary tumour/alveolar tumour ratio was about l.14 in the 
transgenic group and 1.79 in the non-transgenic group (16/14 and 34/19, Table 6.3). The 
transgenic mice had more alveolar and fewer papillary tumours per mouse than the non-
transgenic littermates, with the difference in papillary tumour numbers being more pronounced. 
The largest difference between transgenic and non-transgenic, however, was in the number of 
undetermined tumours (0.67 per transgenic mouse and 2.4 per non-transgenic mouse). The 
difference was not statistically significant (X2= 3.56, p>O.05). 
Table 6.3: Counts of papillary and alveolar tumours after treatment with ethyl 
carbamate. 
n Papillary Alveolar 
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Undetennined 
Total Mean±SD Total Mean±SD Total Mean±SD 
TG 3 16 5.3±1.1 14 4.7 ±2.5 2 0.67 ±0.58 
NTG 5 34 6.8 ± 1.5 19 3.8 ± 1.5 12 2.4±0.89 
TG: transgenic. NTG: non-transgenic. n: number of mice in each group. 
There was no statistically significant difference in alveolar and papillary tumour numbers between 
sexes (X2=o.521, p>O.05, Table 6.4), but conclusions cannot be drawn because of the small 
numbers of animals. 
Table 6.4: Counts of papillary and alveolar tumours after treatment with ethyl 
carbamate. 
n Papillary Alveolar Undetermined 
Male 2 13 11 4 
Female 6 37 22 10 
6.4 ras mutations 
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In order to further investigate the relatively small reduction in tumour multiplicity in the· 
transgenic group, the status of the ras genes in control and transgenic mice was 
investigated.-Direct sequencing of PCR~amplified ras sequence from mouse lung tumours 
showed mutations in both transgenic and control groups (Figure 6.10 and Table 6.5). In the 
non-transgenic group, 11 tumours had a ras mutation in codon 61, 4 had a mutation in 
codon 12 and one tumour did not show any detectable ras mutation, whereas in the 
transgenic group, 13 tumours had a mutation in codon 61, 1 had a mutation in codon 12, 
and one did not have any detectable mutation. When a mutation was detected, the sequence 
corresponding to wild-type ras was also present, showing that the tumour cells where 
heterozygous for the mutated ras allele. No mutations were detected in non-tumour lung 
tissue from 1 control and 2 transgenic mice. The various types of mutations found are 
detailed in Table 6.6. 
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Figure 6.10: Identification of K-ras codon J 2 and codon 6 J mutations by direct 
sequencing of PCR-amplified lung tumour DNA. The primers used fo r 
PCR and sequencing were described in materi als and methods. The 
sequence shown is that of the sense strand for codon 6 J and the anti sense 
strand fo r codon 12. a-d: exon 2 (codon 6 1). e, f: exon I (codon 12). 
Mutati ons are noted by the nucJeotide~ encJ o~ed in boxes. Note that the 
tumour samples in b-d and f contain both the mu tated and the wild-type K-
ras allele. 
Table 6.5: K-ras mutations in transgenic and control mouse lung tumours induced by 
ethy I carbamate 
Codon 61 Codon 12 ND Total 
. Transgenic 13 1 1 15 
Non-transgenic 11 4 1 16 
The numbers in the table are numbers of tumours with the specified mutation. One tumour 
in each group did not have any detectable mutation in the regions sequenced (ND, not 
detectable). All other tumours had a ras mutation either in codon 12 or in codon 61. 
Table 6.6: Spectrum of K-ras mutations in ethyl carbamate-induced lung tumours from 
transgenic and control mice. 
Codon 61 Codon 12 
Normal Mutated Normal Mutated 
CAA CTA CGA CAT GGT GAT 
Transgenic 2 9 2 2 14 1 
Non-transgenic 5 10 1 0 12 4 
147 
148 
6.5 Discussion 
Transgenic mice were produced with 2 constructs containing human Krev-l. Expression in the 
lungs was found in 2 out- of3 UGKREV tested lines and 3 out of 3 UKH tested lines. Overall, 
the level of transgenic Krev-l mRNA expression in the lungs was much lower than expected 
given that, in our experience, Northern blots of RNA from transgenic mice harbouring various 
heterologous genes under the control of the UG promoter show a strong signal corresponding to 
the transgene (DeMayo et at 1991b, Figure 6.3) whereas Krev-l transgene expression was 
hardly detectable by Northern blotting. 
In order to improve the level of expression, introns from the lINE gene were included in the 
UKH construct. cDNAs alone are often poorly expressed in transgenic mice (Palmiter and 
Brinster 1986) and introns have been shown to increase the level of expression of transgenes in 
mice (Palmiter et at 1991). Indeed we have previously shown strong expression of lINE driven 
by the UG promoter in transgenic mouse lung (Chapter 5). The mutated Krev-1 (Glu63) 
-- included in pUKHhas been shown to be a more potent tumour suppressor than Wild-type Krev-
1 in tissue culture (Kitayama et al1990). 
Including lINE introns in the UKH construct did not improve the level of trans gene expression 
and probably resulted in alternative splicing as suggested by the presence of 2 bands in the 
Northern blot (Figure 6.3) and by the presence of a 500-bp band in the RPA (Figure 6.8). The 
RP A, however, also showed a band of the expected size, suggesting that some transgenic Krev-l 
mRNA was properly spliced. Only a small fraction of transgenic Krev-l in UKH mice was 
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properly spliced as the 620-bp band corresponding to the properly spliced transgenic Krev-l 
was less intense than the 500-bp band. 
This low level of expression is surprising since other UG-based constructs have given very strong 
expression in the lungs, even in the absence- of introns (DeMayo et at 1991 b, Margraf et at 
1993). One possible explanation is that overexpression of Krev-l in the lungs is lethal and only 
mice that express low levels of Krev-l, because of position effect, survive. This explanation is 
supported by a Southern blot done on 4 dead mice (2 stillborn, one died on day 5 and one died 
-on day 10 after birth). The day 5 and day 10 mice were transgenic (Figure 6.11). The level of 
lung expression in those mice was not investigated because RNA is degraded very quickly after 
death. An mteresting experiment would be to screen foetuses between days 17 and 20 (after 
UG-driven expression has started and before birth) for trans gene integration and do RP A· with 
lung RNA from transgenic foetuses. Strong Krev-l expression in the lungs of a significant 
number of foetuses would demonstrate that Krev-l overexpressing in the lungs is lethal. 
150 
>. 
0 CL >. 
~ 0 CL 
C () 0 
0 () 0 1 0 ~ ~ 4 5 2 3 
3.6 kb -. 
1.6 kb -. 
Figure 6.11: Southern blot of mouse tail DNA digested with Bgi IT and probed with 32p 
labelled UG3.3. 
DNA was extracted ji·OtTI a live new-born mouse of unknown transgenic status 
(number 1449, lane I), a mouse that died on day 10 after birth (lane 2), still born 
mice (lanes 3 and 4) and a mouse that died on day 5 (lane 5). I and 10 copy are 
non-transgenic mouse tail DNA plus the amount of UGKREV that corresponds 
to 1 and 10 copies of transgene per haploid mouse genome, respectively. 
Control is non-transgenic mouse tail DNA. Two transgenic mice are identified in 
this blot. 
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Endogenous Krev-1 was almost undetectable by RP A. Long exposure of an RP A gel (Figure 
6.6) revealed a very faint band of about 600 bp in wild-type mouse lungs correspondinK to wild-
type Krev-1. Since RPA is 10 times more sensitive than Northern blotting, we did not expect to 
detect endogenous Krev-1 by Northern. Thus, the 1.8-kb band seen in Figures 6.1 and 6.2 is 
probably not Krev-l but another member of the ras gene superfamily. Moreover this 1.8-kb 
band is present in Northern blot of RNA from cell line U937 (Figure 6.2) which expresses very 
little Krev-l, as shown by immunoblotting (Klinz et al 1992). 
Thus, since endogenous Krev-l expression is almost undetectable by RP A, whereas transgenic 
Krev-l is easily detectable, despite low, both UGKREV and UKH constructs resulted in 
transgenic mice with a significant increase of Krev-l expression relative to the very low level of 
endogenous Krev-l expression in the lungs. 
To determine the effect of Krev-l overexpression in the lungs, mice from 3 lines were given 
ethyl carbamate and the numbers of lung tumours were compared between transgenic mice and 
non-transgenic littermates. Overall, there was a reduction of 20% of the number of tumours in 
transgenic mice compared with non-transgenic littermates. 
The relatively small reduction of tumour multiplicity in the transgenic group could be explained 
by the low level of Krev-l expression in the lungs, and is consistent with experiments in tissue 
culture which have shown that Krev-l reverts only a small percentage of transfected cells and 
that its tumour suppressor effect depends on its level of expression (Kitayama et al 1989). The 
larger effect seen in line 2584 could be accounted for by the greater potency of Krev-l (Glu63). 
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However this does not explain why the reduction in tumour multiplicity was minimal in line 
2610. 
After challenge with ethyl carbamate, mice develop 2 kinds of lung tumours, papillary and 
-alveolar. The papillary tumours are thought to arise from Clara cells, whereas the alveolar 
tumours are believed to be derived from alveolar type 2 cells. Thus, another possibility is that 
expression of the transgene acted only on one type of tumour. The proportion of papillary 
tumours varies from strain to strain. In the AI] strain, papillary origin is reported to be 14% of 
total tumours (Beer and Malkinson 1985) while in the SRW strain the proportion is unknown. 
Since the UG promoter directs expression of heterologous genes specifically to the Clara cells 
(Margraf et al1993) the Krev-l transgene may prevent the incidence only of papillary tumours 
and the differences in tumour reduction seen between lines may reflect the differences in the 
proportion of papillary tumours. 
To fmd out whether the reduction in tumour numbers was due solely to a decrease in papillary 
tumours, lung sections were examined and papillary and alveolar tumours were counted. A 
small reduction in papillary and mixed tumour numbers was observed in transgenic mice. 
Although the difference was not statistically significant, due probably to the small number of 
animals, this experiment suggests that expression of Krev-l in transgenic mice preferentially 
suppresses papillary and mixed tumours without affecting the development of alveolar tumours. 
Since it has been established by immunoelectron microscopy that the site of expression of UG-
driven transgenes is the Clara cell (Margraf et al 1993), these results are consistent with the 
Clara-cell origin of papillary tumours. 
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Unfortunately there is no biochemical marker for Clara cell-derived adenomas. Using 
immunohistochemistry with a Clara cell antigen-specific antibody, Ward (1985) detected 
immunoreactivity only in normal Clara cells but not in spontaneous or chemically induced mouse 
lung tumours. Furthermore, transgenic mice with a UG-SV 40 T antigen construct expressed the 
- transgene and the Clara cell protein only at the initial stages of-tumour development (Sandmoller 
et al 1995). Therefore the reduction in tumour multiplicity associated with the expression of 
Krev-l in Clara cells constitutes the only index of Clara cell-derived tumours. 
We recognise that the histology data are not conclusive, since the difference in- numbers of 
alveolar and papillary tumours between transgenic and non-transgenic mice is not statistically 
significant. We also recognise the need to demonstrate expression of the Krev-l transgene in 
Clara cells but not alveolar cells for a defInite answer. A histological analysis with a large 
number of animals (for statistical significance) and immunoelectron microscopy (to conflfITl that 
Krev-1 is expressed in Clara cells and not alveolar cells) could not be done because of time and 
budget constraints. However the encouraging results of this pilot study make the case for a 
larger and more in-depth experiment where more animals and electron microscopy would be 
used. 
Why the development of papillary tumours was only partially prevented remains unclear. 
Possibly not all papillary tumours were derived from Clara cells. The remainder may have been 
more advanced tumours derived from alveolar adenoma (Kimura 1971) which would not have 
been inhibited by Krev-l as the cells from which they originate (type II cells) do not express the 
transgene This interpretation is supported by the presence of tumours which have features of 
both alveolar and papillary tumours. An alternative explanation is that some Clara cell-derived 
papillary tumours escaped suppression by Krev-l, possibly due to cell-to-cell variability in the 
level of expression of the transgene. 
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The limited suppression of the development of papillary tumours by Krev-l may also be due 
to-specifity of Krev-l for a particular type of ras mutations. The differencein incidence of 
K-ras codon 12 mutations between tumours from transgenic and control mice suggests that 
the tumour suppressor activity of Krev-l may be limited to ras proteins that harbour a 
mutation at residue 12. Very scarce data is available in the literature about the specificity of 
Krev-l in regard to the location of the ras mutation. Most of the initial experiments that 
have demonstrated the tumour suppressor activity of Krev-l in tissue culture have been 
carried out in a DT cell line harbouring a_viral ras (Kitayama et al 1989, 1990) which has a 
valine at position 12, as opposed to glycine in the wild-type mouse and human ras. Sato et 
al (1994) investigated the tumorigenicity of cell lines HT 1080 and SW 480 after 
transfection with a Krev-l expression vector by inoculation into nude mice. While both 
transfected cell lines remained tumorigenic, the SW 480 line, which contains a ras mutation 
at codon 12, exhibited an increased lag time compared with controls before the outgrowth 
of tumours. For the HT 1080 cell line, which contains a ras mutation at codon 61, there 
was no difference between the growth rates of transfected and parental cells (Sato et al 
1994). Thus our data, together with these findings, suggest that Krev-l may preferentially 
suppress tumours with a ras mutation at codon 12. This would explain the small reduction 
in papillary tumour multiplicity in the Krev-l transgenic mice as the majority of AlJ mouse 
lung tumours contain a ras mutation in codon 61 (Table 2) which would not be affected by 
Krev-l overexpression. 
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Krev-l specificity for ras codon 12 mutations is however in contradiction with the findings 
of Caamano et al (1992) who showed a partial reduction in tumourigenicity after 
transfection with Krev-l of cell line Calu-6 which contains a ras mutation at codon 61. 
Since Caamano et al and Sato et al have used different promoters to express Krev-l in the 
tumourigeniccells, it is possible that different levels of Krev-l expression are the reason for 
which the tumourigenic phenotype of Calu-6 was reverted whereas that of HT 1080 was 
not. A possible explanation for all those observations is that at a certain level of expression 
Krev-l reverts the transformed phenotype of cells with ras codon 12 mutation and at a 
higher level of expression, cells with ras codon 61 mutations are also reverted. 
Chapter 7 
Conclusion and future work 
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The -aims of this work were to produce transgenic mouse models for 2 serious human lung 
diseases, cancer and emphysema. 
The specific goals were: 
• To further investigate the elastase anti-elastase theory on the development of human 
emphysema. 
• To produce an animal model that could be used to evaluate potential therapies of emphysema. 
• To develop a transgenic mouse model for testing putative tumour suppressor genes in vivo. 
• To test the putative tumour suppressor gene Krev-l in the transgenic mouse model. 
During the course of this work a plasmid, pPB74~, was developed that can be used as a positive 
control for end-filling prior to blunt-end ligation. A more efficient method for blunt-end ligation 
was also developed, where ligation is done first at high DNA concentration to favour 
intermolecular ligation then at low concentration to favour circularisation of the newly formed 
recombinant plasmids (Damak and Bullock, 1993). 
Transgenic mice expressing high levels of HNE in the lungs did not develop emphysema and, 
although there was indirect evidence that some of the enzyme was secreted in an active form, 
there is no direct evidence for activity. Failure to develop emphysema by these animals might 
challenge the elastase-antielastase theory but the evidence for elastase activity in the lungs of 
transgenic mice was not strong enough. Therefore the results are inconclusive. 
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It would be interesting to breed this lINE transgene into a pallid mouse background. The pallid 
mouse has low level of ai-antitrypsin and develops emphysema at a late age (12 months onwards, 
Martorana et alI993). It would be interesting to find out whether expression of lINE in the lungs 
of the pallid mice would result in emphysema developing at earlier age than wild-type pallid mice. 
If the transgenic mice secrete active elastase and the elastase-antielastase theory is correct, the 
equilibrium should shift even more towards emphysema in the transgenic pallid mice and the 
disease may develop at an earlier age in pallid transgenic mice. 
Since there is not a definite proof that lINE is processed in the lungs of UGlINE transgenic mice, 
more experiments need to be doneto clarify this point-One way would beto purify and sequence 
lINE from broncho-alveolar lavages of transgenic mice. Absence of the Pro-N sequence would 
be the proof that lINE is processed. 
If lINE is not processed, other constructs may be tried. A construct where the 6 bp encoding for 
the proN region are removed may result in the synthesis of active elastase. 
We have also developed a transgenic mouse model for testing putative tumour suppressor 
genes in vivo. The model takes advantage of the sensitivity of the AlJ mouse to lung cancer 
and of the ability of the rabbit utero globin promoter to direct expression of heterologous genes 
to the cells from which at least some of the tumours originate. This model has many 
advantages over the commonly used model where transfected cells are grafted into nude mice. 
In particular, the foreign gene is expressed in autologous cells within their natural 
environment,and the mouse host has a normal immune system. 
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This model has been used to test the tumour suppressor activity of Krev-l in vivo. Transgenic 
mice expressing Krev-l in their lungs showed a significant reduction in the number of lung 
tumours strongly suggesting a tumour suppressor effect of Krev-l in vivo. 
The model will be applicable to other candidate tumour suppressor genes. The system could 
also be modified by expressing tumour suppressor genes under the control of an inducible 
promoter to test their effect on existing lung tumours. 
Transgenic mouse models can be very useful tools to gain further understanding of human 
diseases, but can also result in unexpected or undesirable phenotypes. The two models 
developed in this work illustrate these points. While the emphysema model is in need of more 
refinements, the tumour suppressor model proved to be very useful, and was used to show for 
the first time that Krev-l has a tumour suppressor activity in vivo. 
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Appendix I 
Transgenic mice 
Microinjection and transfer of mouse embryos 
A.I.I Introduction 
The transfer of foreign or altered genes to the murine genome consists of several steps. 
Donor mice are given a superovulatory regimen of gonadotropins to maximise the production 
of one-cell embryos. The embryos are collected from the oviducts of the donors and DNA is 
microinjected into the pronucleus of embryos. The surviving embryos are then cultured and 
await transfer. Recipient female mice are hormonally synchronised to serve as foster mothers 
for the microinjected embryos. The embryos are surgically transferred to the oviducts of 
recipient mice and allowed to be carried to term. Pups born from embryo transfer are then 
analysed by Southern analysis of DNA from tail biopsies taken at weaning. 
The following protocol was initially developed to allow one person to carry out all processes 
from superovulation of mice to screening of mice for the presence of the transgene. Also, it 
minimises the number of animals needed to produce transgenic mice, and can be scaled in 
either direction to suit the needs of the investigating laboratory. This protocol is essentially as 
developed by Dr Franco DeMayo and Professor David Bullock at Baylor College of 
Medicine, Houston, Tx , with some modifications introduced at Lincoln. 
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A.t.2 Embryo collection 
A.t.2.t Superovulation 
A.l.2.t.t Donor mice 
Young immature mice respond better to superovulation than older animals. The response to 
the gonadotropin regimen is also strain-dependent. We currently use 6 weeks old Swiss 
Random White (SRW) purchased from the Animal Breeding Station, Mosgiel. 
A.t.2.1.2 Gonadotropin regimen 
a 5 IUPMSG(Sigma) ip betweenlO.OOam and1.00pm on Day 1. 
b 5 ill heG (Sigma) ip between 8.00am and 9.00am on Day 3. 
A.1.2.t.3 Mating 
a The donor females are paired singly with SRW males at 4.00pm on Day 3. The males 
should be older than 3 months and younger than 18 months. 
b The females are removed from the males at 8.00am - 9.00am the next day and 
examined for the presence of a vaginal plug. Records are kept on the males' performance. 
Males with 3 successive failures to plug females are culled. 
A.1.2.2 Flushing of the oviducts 
Our mice are housed with lights on from 5.00am to 7.00pm. Using this light cycle and using 
the previously described superovulation regimen we collect embryos from the females 
between 9.00am and 11.00am on -the day after mating. This ensures a maximum number of 
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fertilised and injectable embryos (embryos with visible pronuclei) with a minimum number of 
cleaved embryos. 
1 Females are sacrificed by cervical dislocation. 
2 Abdomen is washed with 70% EtOH. 
3 Abdomen is opened by mid-ventral incision. 
4 Oviduct is removed. 
5 Under magnification of 12x, the oviduct is flushed with 0.2ml of culture medium into 
a depression slide using a 30 gauge needle and tuberculin syringe. The needle is blunted by 
rubbing the tip on sandpaper and is inserted through the fimbria (the adovarian opening to the 
oviduct). 
6 The embryos are -collected from the depression slide with a hand-drawn transfer 
pipette. The transfer pipette is a Pasteur pipette whose stem has been pulled over a flame so 
its diameter is slightly larger than that of a mouse embryo. All collection is accomplished by 
mouth pipetting. 
7 If the embryos are encased in cumulus cells, they are placed in medium containing 
0.1 % hyaluronidase until they are free of the cumulus mass (within 1 to 2 min), observed 
under a dissection microscope. 
8 After the embryos are freed from the cumulus mass, the injectable embryos are 
separated from the nonfertilized and fragmented embryos. (Injectable embryos are embryos 
which contain 2 polar bodies and whose pronuclei can be seen at 25x under the dissecting 
scope). 
9 The injectable embryos are washed twice in fresh medium and placed In culture 
medium at 37°C under 5% CO2 in air until injection. 
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A.l.3 Embryo Culture 
A.1.3.1 Medium 
Embryos are cultured in microdrops of medium covered with Silicon oil (Dow Corning 200 
. Fluid) jn 60 x 15 mm culture dishes. 
The medium is Whittingham's HT6 medium supplemented with 5 mg/ml BSA (Quinn et al 
1982) 
A.1.3.2 Culture 
Rour microdropsof approximately O.lmlof medium are spotted onto a 60 x 15 mm culture 
dish. Ten ml of Silicon oil are then poured on top of the drops. Embryos can be placed·in the 
drops and cultured in an atmosphere of 5% CO2 in air at 37°C. 
A.1.4 Microinjection 
A.l.4.1 Preparation of needles 
The needles used are microcapillary tubing from World Precision Instruments (injection 
needles) and 10 ~l glass disposable micropipettes from CMS (holding needles). The pipettes 
are pulled on a Sutter Instrument micropipette puller with heat setting at 400, pull at 250, 
velocity at 100 and time at 180 (program 4). The setting will vary for different micropipette 
pullers. No further manipulation is required for the injection needle. 
191 
The embryo holding needle is cut and polished using a micro-forge. Cutting the holding 
needle is accomplished by bringing the needle against the microforge filament- glass ball with 
heat at 2.5. Once the needle starts melting, the glass ball is rapidly cooled down by turning 
the blower on. The tip of the holding needle should be the size of the embryo (about 100 
/lm). The approximate place to break the-holding needle can only be learned with practice. 
After breaking the holding needle, its edges are polished by bringing the needle tip close to 
the glass ball of the microforge and heating it for 3 sec at a heat setting of 3.5. The tip of the 
needle must not touch the glass balL 
The holding needle must be bent by· heating the needle over the glass ball in the microforge at 
a heat setting of 3.5. The needles are held at a 750 angle to the horizontal over the ball; they 
are heated until the proper angle is achieved. The angle of bending is about 150. 
The holding needle is fitted to K19 teflon tubing prefilled with paraffin oil then mounted on 
the micromanipulator. The holding needle is filled by pushing paraffin oil through with the 
use of a Stoelting micrometer syringe. The holding needle will fill easily. Make sure there are 
no air bubbles. 
A.1.4.2 DNA preparation 
The DNA fragment for microinjection should be freed from all procaryotic sequences (i.e. 
plasmid vector). This is accomplished by digestion with the appropriate restriction 
endonuclease(s) and electrophoretic separation of the DNA fragments on an agarose gel. The 
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fragment can then be isolated from the gel and purified by the glass milk purification method 
using the GlassMax kit (Life Technologies}. 
The purified DNA is quantified by running an aliquot through an agarose gel containing 
ethidium bromide and comparing the inttmsity. of the -band to that of molecular weight 
markers of known concentration. The DNA can then be diluted to a concentration of 2 Ilg/ml 
in 10 mM Tris pH 7.5; 0.25mM EDTA. 
A.l.4.3 Injection of the embryos 
The embryos are placed in the injection chamber in a 25 III drop of media. The injection 
chamber consists of the -lid of a- Falcon 1007 Petrie dish. -We recommend Hoffman or 
Normarski optics for microinjection. 
Inside the chamber is the 25 III drop of media containing the embryos overlaid with silicon oil. 
Once the injection chamber is prepared microinjection can proceed. The injection needle is 
put in the DNA solution in a microfuge tube upside down. It fills after 1 or 2 minutes by 
capillary action and is then fitted to the teflon tubing. The injection chamber is then moved 
until the embryos are in focus and both needles are lowered into the drop. The embryos can 
now be injected. The injection needle in polished against the holding needle to make a small 
opemng. 
1 Under 40x the embryo is picked up with suction by the holding needle. 
2 The injecting needle is positioned next to the embryo. 
3 Magnification is increased to 400x. 
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4 The microscope is focused until the pronucleus is visible; its nuclear membrane must 
not be confused with its nucleolar membrane. 
5 Once the pronuclear membrane is in focus, the injecting needle is lowered until it is in 
the same focal plane as the nuclear membrane. 
6 The injecting needle is then moved into the pronucleus and DNA injected while 
observing pronuclear swelling. 
7 The amount of DNA you can inject into the pronucleus is about 2 pI. This is an 
approximate 50% increase in the diameter of the pronucleus. Only practice will give you the 
ability to see how~muchyou can swell the pronucleus without killing the embryo. If the 
pronucleus did not swell, you did not achieve a successful injection. These steps are repeated 
until alLembryos are injected. Injected embryos are moved to the bottom of the drop so they 
do not get mixed up with non-injected ones. 
After injection, the embryos are washed twice in medium. The embryos which survived 
microinjection, as judged by the appearance of normal morphology, are then placed in culture 
until transfer. 
A.1.S Embryo transfer 
A.I.S.I Recipient mice 
1 The recipients used are Swiss Random White females about 3 months old. 
2 The mice used to mate with the recipients are vasectomized Swiss Random White 
males. The most difficult process of this entire system is the embryo transfer. Successful 
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embryo transfer depends not only on the viability of the embryo, but also on the ability of the 
foster mother to support a full term pregnancy. 
A.1.S.2 Preparation of recipients by natural mating 
1 SRW females are placed with vasectomizedSRW males on the day prior to embryo 
collection. 
2 Females are checked for the presence of a vaginal plug at 8:00 - 9:00 am on the day of 
injection. Only females with visible plugs will serve as recipients. 
Since natural mating is a function of the four day cycle of the female mouse, ensuring enough 
recipients for embryo transfer requires a large number of random cycling females to be placed 
with males. To minimise the number of females necessary for mating we utilise hormonal 
synchronisation of the female oestrus cycle. 
A.1.S.3 Preparation of recipients by hormonal induction 
1 Day 1,2 ru PMS ip, 10:00 am - 1:00 pm. 
2 Placed with vasectomized SRW males on Day 3 
3 Checked for plug at 8:00 - 9:00 am on Day 4. NOTE: Only females with visible 
vaginal plug, proof of mating, will serve as recipients. 
A.l.S.4 Embryo transfer 
Anaesthesia - Avertin can be used. The female is given 0.6 ml of Avertin. The animal 
will reach surgical anaesthesia in 3-5 min and be under for 20-30 min. 
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2 The transfer pipette, made as for embryo collection, is filled with medium, a small air 
bubble and the embryos. (The volume containing the embryos must be minimal). The air 
bubble serves as a marker to show where the embryos have been transferred. 
3 The hair on the dorsolateral side of the female is clipped. 
4 The female is laid on ·her side and her dorsolateral side is washed with 70% EtOH. 
5 A small incision between the rib cage and the knee is made and the ovary/oviduct is 
exposed by grasping the periovarian fat with forceps. 
6 Using fine tweezers, an incision is made in the ovarian bursa to expose the fimbria of 
the oviduct. 
7 Under 4x magnification, the pipette is inserted through the fimbria into the oviduct 
and embryos expelled until you can see the air bubble in the oviduct. 
8 The oviduct is then placed back into the peritoneal cavity. 
9 The wound is closed with a wound clip. 
10 The mouse is placed on a heating pad (40°C) until it recovers from anaesthesia. 
11 Transfers are done to one side only, with 15 - 20 embryos transferred per mouse. 
A.l.6 Assessment of success 
The gestation period of the mouse is on average 21 days. Tail biopsies can be taken at 
weaning and DNA isolated from the tails can be probed to detect the presence of the 
transgene. Three to four weeks after birth the mouse is ready to be weaned. Weaning is the 
most appropriate time to take tail biopsies from mice for isolation of DNA. At this time the 
mouse can be numbered by ear tag. 
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A.l.6.1 Efficiencies ofmicFoinjection 
The following are the efficiencies one should expect from microinjection of mouse embryos. 
Embryo collection ..... 15 to 30 embryos/mated female 
Survival of microinjection ..... 50 to 70% 
Pregnancy rate of recipients ..... 30 - 70% 
Mice born/embryo transferred ..... 10 to 30% 
Transgenic mice ..... 10 to 30% of mice born. 0.5 to 2.0% of embryos injected. 
A.1.7 Solutions used in making transgenic mice 
A.1.7.1 HT6 medium 
A.1.7.1.1 Composition 
Component 
NaCl 
KCl 
MgCh.6H2O 
Na2HP04 
CaCh.2H2O 
NaHC03 
Hepes 
Na lactate 
Na pyruvate 
Glucose 
Penstrep 
Phenol Red 
BSA (OrnCO) 
rnM g/lOO ml 
99.40 0.581 
1.42 0.011 
0.47 0.0096 
0.36 0.0097 
1.78 0.0262 
4.00 0.0336 
21.00 0.5 
24.90' 0.465 ml 
0.47 0.0052 
5.56 0.1 
100 U/mlll OO~g/ml 1.0 ml 
.001% w/v 0.1 ml 
5 mg/ml 0.5 g 
g/500 ml 
2.905 
0.055 
0.048 
0.0255 
0.131 
0.168 
2.5 
2.325 
0.026 
0.5 
lOml 
0.5 ml 
2.5g 
pH is adjusted to 7.4 with NaOH, the medium sterilised by filtration through 0.25 ~m 
Millipore filter and stored at 4 DC. 
BSA is added freshly the day of injection. 
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A.1.7.1.2 Preparation of HT6 medium from concentrated stocks 
Stock A 10 x g/lOO mls g/50 mls gllO ml g/15 mls 
NaCI 5.81 2.905 
KCI 0.11 0.055 
MgCh.6H2O 0.096 0.048 
Na2HP04 0.051 0.0255 
NaLactate 4.65 mls 2.325 mls 
Glucose 1.00 0.50 
PenStrep 20mls 10mls 
STOCKB lOx 
fresh every 2 weeks 
NaHC03 0.336 0.168 0.034 0.051 
STOCK C 100 x 
fresh every_ 2 weeks 
NaPyruvate 0.052 
STOCKD 100x 
CaCh.2H2O 0.262 
STOCKE lOx 
Hepes 5.0 2.5 
Phenol Red 1 ml 0.5ml 
pH to 7.4 with 1 N HCI 
1 Make up in sterile tube with dd. water 
2 Filter into 50 ml tube for A, E. 
Filter into 15 ml tube for B, C, D. 
HT6 working solution from concentrated stocks 
STOCK 
A (rnl) 
B (ml) 
C (ml) 
D (ml) 
E (ml) 
dd.water (ml) 
10 rnIs 
1 
1 
0.1 
0.1 
1 
6.8 
1. Make in sterile 50 ml tube. 
25 mls 
2.5 
2.5 
0.25 
0.25 
2.5 
17 
50mls 
5 
5 
0.5 
0.5 
5 
34 
100 rnIs 
10 
10 
1 
1 
10 
68 
2. Pour into sterile 15 ml Falcon tubes in 10 ml aliquots. Keep media at 4DC for up to 2 
weeks. 
3. Prior to use, add 0.66 mls BSA to 10 ml aliquot. 
The above preparations need to be carried out in a laminarflow cabinet. 
A.t.7.2 PMSG 
- make fresh every 3 weeks 
- store stock and aliquots in freezer (-20°C) 
Stock solution 
1 Add 2 mls 0.9% NaCl to 1000 ru PMS powder (500 ru/ml). 
2 Dispense 100 ~l into Eppendorf tubes and keep at _20DC 
Working solution 
1 Add 0.9 mls 0.9% NaCl to aliquot. 
2 Administer 0.1 ml (5 IU) to each donor. 
0.04 ml (2 IU) to each recipient. 
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A.1.7.3 HeG 
Stock solution 
1 Add 5.0 ml sterile dd.water to 2500 IV powder (500 IV/ml). 
2 Dispense in 100 J.lI aliquots (50 IV/tube), dry in speed-vac for about 2 hours, keep at -
20°C 
Working solution 
1 Add 1.0 ml 0.9% NaCI to aliquot. 
2 Administer 0.1 ml to donors. 
A.1.7.4HYALURONIDASE 
Stock solution 
Dissolve 0.1 g hyaluronidase in 5 ml O.lM NaCl 
Dispense in 125 J.lI aliquots. 
Working solution 
Add 125 J.lI stock solution to 2.5 rn1 HT6 medium 
Store at +4°C. 
A.1.7.S MTE 
1M Tris (pH 7.5) 
0.5MEDTA 
dd.water to 
1ml 
50 J.lI 
100 mls 
10mM 
0.25mM 
Filter, dispense into 50 J.lI aliquots, and keep at _20DC 
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A.l.7.6 AVERTIN 
Stock solution 
Tribromoethanol (Aldrich-2, 2, 2-tribromoEtOH) 12.5 g 
Amylene hydrate (tert. amyl alcohol or 2-methyl butanol) 7.75 ml 
Dissolve in 3r C waterbath overnight if necessary. 
Keep covered (very noxious), store in glass, protect from light. 
Working solution 
Saline-(0.9% NaCl) 
A vertin stock 
Stir several hours. 
40ml 
0.5 ml 
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Item 
Enzymes 
Alkaline phosphatase 
DNA polymerase I (Klenow) 
Pronase 
Restriction enzymes 
T4 DNA ligase 
Tag DNA polymerase 
Plasmids 
pBluescript SK 
pPB74 
pPBl5 
pKrev-l 
pKrevG63 
pUGl1. 8 
Appendix 2 
Materials and suppliers 
Supplier 
Boehringer-Mannheim 
Boehringer-Mannheim 
Boehringer-Mannheim 
Boehringer-Mannheim 
New England Biolabs 
Boehringer-Mannheim 
Boehringer-Mannheim 
Stratagene 
Dr M. Brantly 
Dr M. Brantly 
PrM. Noda 
PrM. Noda 
PrD.W. Bullock. 
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Address 
Mannheim, Germany 
Mannheim, Germany 
Mannheim, Germany 
Mannheim, Germany 
Beverly, MA 
Mannheim, Germany 
Mannheim, Germany 
La Jolla, CA 
NIH, Bethesda, MD 
NllI, Bethesda, MD 
Kyoto University, Japan 
Kyoto University, Japan 
Lincoln University 
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Others 
Agarose FMC Rockland, ME 
Centricon 30 cells Amicon Beverly, MA 
Sephadex G50 Pharmacia Uppsala, Sweden 
CM-cellulosecolumn ~Whatman Maidstone, UK 
DR5acells Life Technologies Gaithersburg, MD 
GeneClean kits Bio 101 La Jolla, Ca 
GeneScreen membranes Dupont Boston,MA 
GlassMax kits Life Technologies . Gaithersburg, MD 
RCG Sigma StLouis, MO 
Magic Miniprepstm columns Promega Madison, WI. 
Megaprime labelling kits Amersham Buckinghamshire, UK 
Mice Animal Breeding Station Mosgiel, New Zealand 
N-methoxy-succinyl-Ala-
Ala-Pro-Val p-Nitroanilide Sigma StLouis, MO 
PD 1 0 columns Pharmacia Uppsala, Sweden 
PMSG Sigma StLouis, MO 
Radioisotopes Amersham Buckinghamshire, UK 
RPA kits Ambion Austin, TX 
Sequencing kit Promega Madison, WI. 
Streptavidin-biotin-horse 
radish peroxidase conjugate Amersham Buckinghamshire, UK 
U937 cell line Clonetech Palo Alto, CA 
X-Ray films Kodak Rochester, NY 
] Appendix 3 
DNA extraction from mouse tails 
. 1. Store tissue which has been cut into -4-6 pieces on ice then, in the freezer until required. 
2. Add 0.7 rnl Pronase solution 
3. Secure lids, Sellotape in place in rack. Place in 37° C shaking incubator overnight. The 
rack should be positioned so that the tubes are horizontal. 
4. Add 0.4 rnl phenol (TE buffered no more than 2 weeks previously) and 0.4 rnl 
chloroform: isoamyl alcohol (24: 1) 
5. Vortex for 20 sees. 
6. Microfuge 5 mins at 4°C at 10 OOOg. 
7. Transfer upper phase (aqueous) to a fresh microfuge tube without disturbing interface 
(approx. 0.5 rnI) 
8. Add 1 rnl absolute Ethanol at -20°e. 
9. Mix by inverting tube several times, vortex for a few seconds. 
10. Spin 5 mins at 4°C at 10 OOOg. 
11. Pour off Ethanol. 
12. Add 1 rnl 70% Ethanol. 
13. Spin 5mins at 10 OOOg. 
14. Pour off EtOH. 
15. Dry in speed vac. 5 mins. 
16. Add 0.2 rnl TE. 
17. Allow DNA to dissolve at least 3 hrs in fridge. 
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18. Reprecipitate DNA 
Add 1110 vol. 
2 vols 
3 M NaOAc(pH 5.2) 
EtOH absol. 
19. Spin, wash, dissolve in TE as before. 
20. Measure OD: 
(20 ~l) 
(440 ~l) 
dilute 5 ~l in 495 ~l TE. For blank, use 500 ~l TE. Vortex samples well before 
pipetting. 
OD 260 x 5 = concentration ~gI~1 
OD 2601280 should be greater than 1.3 for sufficient purity. 
DNA extracted this way is suitable for Southern analysis. 
DNA should be diluted 5 x for peR. 
SOLUTIONS 
Pronase Solution 
Make fresh 
10 x SET 
10% SDS 
dd.water 
Pronase (20 mg/rnl) 
0.5 rnl 
0.5 rnl 
3.875 rnl. 
0.125 rnl (2.5 mg) 
5.0 rnls 
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10 x SET 
NaCl 
Tris 
EDTA 
4.383 g 
1.21 g 
0.186 g 
Bring to 40.00 mls with H20, pH to 7.8, make up to 50 mls 
Autoclave 
Store at room temperature 
Pronase aIiquots 
0.1 g Pronase in 5 mls dd. water 
Filter 
Dispense in aliquots of 125 /-11 in autoclaved Eppendorftubes 
Store in freezer at -20°e. 
I.5M 
0.2M 
10mM 
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Appendix 4 
peR screening of transgenic mice 
- All pipetting in PCR room. 
- No DNA pipettingwiththe "no DNA" pipeaes. 
- Wear gloves. 
- Vortex all solutions well before use. 
1. Label n O. 75rnl rnicrofuge tubes for n DNA samples to be analysed. 
2. In a microfuge tube mix: 
Working solution Primer 1 
Working solution Primer 2 
Mix well. 
3. Add 10 ~l of primers mix to each tube. 
4. Add 1 ~l of DNA to each tube. 
5 ~l x (n+l) 
5 ~l x (n+l) 
5. Put tubes on PCR plate, denature at 94°C 1 min. 
Set PCR plate to 72°C while master mix is prepared. 
6. Master mix-
10 X dNTP working solution 
lOX reaction buffer 
dd.water 
Taq DNA polymerase 
~l 
5 
5 
30 
0.3 
40 
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) 
) prepare 
)n+l 
7. 
8. 
Vortex the mix well and place on thennocyc1er plate. Add 40 J.lI master mix to each tube. 
Vortex after addition. 
Add 50 J.lI silicon oil to each tube. 
Run programme 
DENATURE 
ANNEAL 
EXTEND 
CYCLES 30 
END 
Close lid tightly. 
TEMP.oC MINUTES 
94 0.2 
55 2 
72 2.5 
72 7 
These parameters are provided by programme 8 (Hybaid machine) or programme 18 
(Autogene machine). 
9. Add 5 J.llioading dye to each tube. 
Run 10 J.lI product on 1.2% agarose gel (take care to avoid oil when loading the gel. 
Photograph. 
WORKING SOLUTIONS 
1. Working solutions of primers: 2.5 J.lM in TE buffer. 
2. Working solution of dNTPs: dATP, dGTP, dCTP, dTTP, 2 mM each, in water. 
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Appendix 5 
Statistical analysis of mouse lung tumour data 
Count: number of lung tumours 
tg: transgenic status of the mouse. 
1: transgenic 
2: non-transgenic 
sex: 1: female 
2: male 
1. All lines 
MTB > GLM 'count' = litter tg sex litter*tg litter*sex sex*tg. 
Factor Levels 
litter 9 
tg 2 
sex 2 
Values 
1 2 3 4 5 6 7 8 9 
1 2 
1 2 
Analysis of Variance for count 
Source DF Seq SS Adj SS AdjMS 
litter 8 3888.50 2885.49 360.69 
tg 1 389.48 338.36 338.36 
sex 1 148.73 6l.95 6l.95 
litter*tg 8 402.59 349.89 43.74 
litter*sex 8 279.36 283.18 35.40 
tg*sex 1 68.35 68.35 68.35 
Error 38 2162.52 2162.52 56.91 
Total 65 7339.53 
F P 
6.34 0.000 
5.95 0.020 
l.09 0.303 
0.77 0.632 
0.62 0.754 
l.20 0.280 
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Unusual Observations for count 
Obs. count Fit Stdev.Fit Residual St.Resid 
1 21.0000 21.0000 7.5438 0.0000 *X 
2 22.0000 37.0000 5.3342 -15.0000 -2.81R 
3 52.0000 37.0000 ·5.3342 15.0000 2.81R 
4 51.0000 51.0000 7.5438 0.0000 *X 
6 8.0000 25.0807 4.1189 -17.0807 -2.70R 
15 12.0000 12.0000 7.5438 0.0000 *X 
25 16.0000 16.0000 7.5438 0.0000 *X 
31 10.0000 18.9215 6.2493 -8.9215 -2.11R 
34 30.0000 21.0785 6.2493 8.9215 2.11R 
R denotes an obs. with a large st. resid. 
X denotes an obs. whose X value gives it large influence. 
MTB > GLM 'count' = litter tg sex; 
SUBC> Means tg sex litter. 
Factor Levels Values 
litter 9 1 2 3 4 5 6 7 8 9 
tg 2 1 2 
sex 2 1 2 
Analysis of Variance for count 
Source DF Seq SS Adj SS AdjMS F P 
litter 8 3888.50 3619.77 452.47 8.54 0.000 
tg 1 389.48 416.36 416.36 7.86 0.007 
sex 1 148.73 148.73 148.73 2.81 0.099 
Error 55 2912.82 2912.82 52.96 
Total 65 7339.53 
Unusual Observations for count 
Obs. count Fit Stdev.Fit Residual St.Resid 
2 22.0000 37.0109 3.6954 -15.0109 -2.39R 
3 52.0000 37.0109 3.6954 14.9891 2.39R 
6 8.0000 25.8560 2.7904 -17.8560 -2.66R 
27 26.0000 11.1091 2.5451 14.8909 2.18R 
R denotes an obs. with a large st. resid. 
Means for count 
tg Mean Stdev 
1 21.70 1.296 
2 26.92 1.345 
sex 
1 22.72 1.262 
2 25.90 1.400 
litter 
1 35.99 3.695 
2 17.60 2.584 
3 30.06 2.615 
4 15.31 2.505 
5 17.80 3.265 
6 16.75 2.573 
7 31.08 2.309 
8 20.52 2.624 
9 33.67 2.971 
2. Line 2584 
MTB > GLM 'count' = litter tg sex litter*tg litter*sex sex*tg. 
Factor 
litter 
tg 
sex 
Levels 
3 
2 
2 
Values 
135 
1 2 
1 2 
Analysis of Variance for count 
Source DF Seq SS 
litter 2 825.8 
tg 1 690.3 
sex 1 97.9 
litter*tg 2 39.7 
litter*sex 2 72.0 
tg*sex 1 28.2 
Error 7 1041.7 
Total 16 2795.5 
Adj SS AdjMS 
425.8 212.9 
454.7 454.7 
68.4 68.4 
26.1 13.1 
94.9 47.4 
28.2 28.2 
1041.7 148.8 
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F P 
1.43 0.301 
3.06 0.124 
0.46 0.520 
0.09 0.917 
0.32 0.737 
0.19 0.677 
Unusual Observations for count 
Obs. count Fit Stdev.Fit Residual 
1 21.0000 21.0000 12.1988 0.0000 
4 51.0000 51.0000 12.1988 0.0000 
11 38.0000 38.0000 12.1988 0.0000 
12 35.0000 35.0000 12.1988 0.0000 
15 12.0000 12.0000 12.1988 0.0000 
X denotes an obs. whose X value gives it large influence. 
MTB > GLM 'count' = litter tg sex; 
SUBC> Means litter tg sex. 
Factor 
litter 
tg 
sex 
Levels 
3 
2 
2 
Values 
135 
1 2 
1 2 
Analysis of Variance for count 
Source DF Seq SS 
litter 2 825.83 
tg 1 690.27 
sex 1 97.85 
Error 12 1181.58 
Total 16 2795.53 
Means for count 
litter Mean Stdev 
1 34.66 5.411 
3 31.89 3.775 
5 18.34 4.521 
tg 
1 22.01 3.675 
2 34.58 3.841 
sex 
1 25.70 3.473 
2 30.89 3.772 
Adj SS AdjMS 
720.03 360.02 
500.61 500.61 
97.85 97.85 
1181.58 98.46 
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St.Resid 
*X 
*X 
*X 
*X 
*X 
F P 
3.66 0.058 
5.08 0.044 
0.99 0.339 
3. Line 2610 
MTB > GLM 'count' = litter tg sex litter*tg litter*sex tg*sex. 
Factor 
litter 
tg 
sex 
Levels 
3 
2 
2 
Values 
249 
1 2 
1 2 
Analysis of Variance for count 
Source DF Seq SS 
litter 2 1523.66 
tg 1 9.78 
sex 1 97.79 
litter*tg 2 34.26 
litter*sex 2 59.06 
tg*sex 1 261.12 
Error 13 687.54 
Total 22 2673.22 
Unusual Observations for count 
Obs. 
8 
count 
16.0000 
Fit 
16.0000 
Adj SS 
849.97 
5.44 
0.85 
134.36 
187.24 
261.12 
687.54 
Stdev.Fit 
7.2724 
AdjMS 
424.98 
5.44 
0.85 
67.18 
93.62 
261.12 
52.89 
Residual 
0.0000 
X denotes an obs. whose X value gives it large influence. 
MTB > GLM 'count' = litter tg sex tg*sex. 
Factor 
litter 
tg 
sex 
Levels 
3 
2 
2 
Values 
249 
1 2 
1 2 
Analysis of Variance for count 
Source DF Seq SS 
litter 2 1523.66 
tg 9.78 
sex 1 97.79 
tg*sex 1 147.17 
Error 17 894.81 
Total 22 2673.22 
Adj SS 
1165.94 
31.37 
98.81 
147.17 
894.81 
AdjMS 
582.97 
31.37 
98.81 
147.17 
52.64 
F 
8.04 
0.10 
0.02 
1.27 
1.77 
4.94 
St.Resid 
*X 
F 
11.08 
0.60 
1.88 
2.80 
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P 
0.005 
0.753 
0.901 
0.313 
0.209 
0.045 
P 
0.001 
0.451 
0.188 
0.113 
MTB > GLM 'count' = litter tg sex 
SUBC> Means litter tg sex. 
Factor 
litter 
tg 
sex 
Levels 
3 
2 
2 
Values 
249 
1 2 
1 2 
Analysis of Variance for count 
Source DF Seq SS 
litter 2 1523.66 
tg 1 9.78 
sex 1 97.79 
Error 18 1041.98 
Total 22 2673.22 
Unusual Observations for count 
Obs. 
10 
count 
26.0000 
Fit 
11.9318 
Adj SS 
1339.02 
19.07 
97.79 
1041.98 
Stdev.Fit 
2.9025 
R denotes an obs. with a large st. resid. 
Means for count 
litter Mean Stdev 
2 17.44 2.724 
4 15.12 2.790 
9 33.67 3.106 
tg 
1 21.13 2.161 
2 23.01 2.451 
sex 
19.83 2.227 
2 24.32 2.517 
AdjMS 
669.51 
19.07 
97.79 
57.89 
Residual 
14.0682 
F 
11.57 
0.33 
1.69 
St.Resid 
2.00R 
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P 
0.001 
0.573 
0.210 
4. Line 1803 
MTB > GLM 'count' = litter tg sex litter*sexlitter*tgsex*tg; 
SUBC> Means litter tg sex. 
Factor 
litter 
tg 
sex 
Levels 
3 
2 
2 
Values 
678 
1 2 
1 2 
Analysis of Variance for count 
Source DF Seq SS 
litter 2 1066.72 
tg 1 70.00 
sex 1 11.34 
litter*sex 2 29.54 
litter*tg 2 8.52 
tg*sex 1 . 4.88 
Error 16 207.49 
Total 25 1398.50 
MTB > GLM 'count' = litter tg sex 
SUBC> Means litter tg sex. 
Factor 
litter 
tg 
sex 
Levels 
3 
2 
2 
Values 
678 
1 2 
1 2 
Analysis of Variance for count 
Source DF Seq SS 
litter 2 1066.72 
tg 1 70.00 
sex 1 11.34 
Error 21 250.43 
Total 25 1398.50 
Adj SS AdjMS 
1003.04 501.52 
67.19 67.19 
11.43 11.43 
27.15 13.57 
5.47 2.74 
4.88 4.88 
207.49 12.97 
Adj SS AdjMS 
1091.91 545.96 
56.32 56.32 
11.34 11.34 
250.43 11.93 
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F P 
38.67 0.000 
5.18 0.037 
0.88 0.362 
1.05 0.374 
0.21 0.812 
0.38 0.548 
F P 
45.78 0.000 
4.72 0.041 
0.95 0.341 
Unusual Observations for count 
Obs. 
6 
count 
8.0000 
Fit 
14.5239 
Stdev.Fit 
1.5163 
R denotes an obs. with a large st. resid. 
Means for count 
litter Mean Stdev 
6 16.75 1.2209 
7 31.54 1.1016 
8 19.64 1.2756 
tg 
1 21.13 1.0096 
2 24.16 0.9476 
sex 
1 23.35 0.9538 
2 21.94 1.0422 
Residual 
-6.5239 
St.Resid 
-2.1OR 
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